Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:panobinostat
go back to main search page
Accession:CHEBI:85990 term browser browse the term
Definition:A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.
Synonyms:exact_synonym: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide
 related_synonym: Formula=C21H23N3O2;   InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+;   InChIKey=FPOHNWQLNRZRFC-ZHACJKMWSA-N;   LBH 589;   LBH589;   SMILES=Cc1[nH]c2ccccc2c1CCNCc1ccc(\\C=C\\C(=O)NO)cc1
 alt_id: MESH:C496932
 xref: CAS:404950-80-7;   Drug_Central:4682;   KEGG:D10319
 xref_mesh: MESH:C496932
 xref: PMID:25305451;   PMID:25377157;   PMID:25410127;   PMID:25458954;   PMID:25572329;   PMID:25608569;   PMID:25612941;   PMID:25628765;   PMID:25710456;   PMID:25802326;   PMID:25837990;   PMID:25870990;   PMID:25904215;   PMID:25939707;   PMID:25944617;   PMID:26000292;   PMID:26030093;   PMID:26051506;   Reaxys:12257756;   Wikipedia:Panobinostat
 cyclic_relationship: is_conjugate_base_of CHEBI:85992


show annotations for term's descendants           Sort by:
 
panobinostat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A2ml1 alpha-2-macroglobulin-like 1 decreases expression ISO Panobinostat results in decreased expression of OVOS2 mRNA CTD PMID:26272509 NCBI chr 4:161,863,609...161,907,897
Ensembl chr 4:161,866,078...161,907,767
JBrowse link
G Abat 4-aminobutyrate aminotransferase increases expression
multiple interactions
ISO panobinostat results in increased expression of ABAT mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABAT mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:7,093,406...7,200,439
Ensembl chr10:7,093,405...7,200,499
JBrowse link
G Abca5 ATP binding cassette subfamily A member 5 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABCA5 mRNA
panobinostat results in decreased expression of ABCA5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:98,573,226...98,645,028
Ensembl chr10:98,576,039...98,644,938
JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ABCG2 mRNA CTD PMID:27188386 NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
JBrowse link
G Abhd14a abhydrolase domain containing 14A decreases expression
multiple interactions
ISO panobinostat results in decreased expression of ABHD14A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ABHD14A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:115,141,575...115,151,222
Ensembl chr 8:115,141,539...115,149,527
JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of ABL1 mRNA CTD PMID:21791302 NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388
JBrowse link
G Acad11 acyl-CoA dehydrogenase family, member 11 increases expression ISO panobinostat results in increased expression of ACAD11 mRNA CTD PMID:26272509 NCBI chr 8:112,594,758...112,676,275
Ensembl chr 8:112,594,691...112,676,280
JBrowse link
G Ackr3 atypical chemokine receptor 3 increases expression
multiple interactions
ISO panobinostat results in increased expression of ACKR3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACKR3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:97,355,881...97,367,455
Ensembl chr 9:97,355,924...97,367,445
JBrowse link
G Acp3 acid phosphatase 3 increases expression
multiple interactions
ISO Panobinostat results in increased expression of ACP3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACP3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:112,838,574...112,884,062
Ensembl chr 8:112,834,707...112,884,077
JBrowse link
G Acsl1 acyl-CoA synthetase long-chain family member 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSL1 mRNA
panobinostat results in increased expression of ACSL1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr16:48,937,456...49,003,898
Ensembl chr16:48,937,456...49,003,246
JBrowse link
G Acsm3 acyl-CoA synthetase medium-chain family member 3 increases expression ISO panobinostat results in increased expression of ACSM3 mRNA CTD PMID:26272509 NCBI chr 1:189,514,504...189,541,233
Ensembl chr 1:189,514,553...189,541,224
JBrowse link
G Acta2 actin alpha 2, smooth muscle decreases expression ISO Panobinostat results in decreased expression of ACTA2 mRNA CTD PMID:30481203 NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
JBrowse link
G Ada adenosine deaminase multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA
panobinostat results in decreased expression of ADA mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:160,115,840...160,139,947
Ensembl chr 3:160,115,842...160,139,947
JBrowse link
G Adam12 ADAM metallopeptidase domain 12 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of ADAM12 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:205,951,840...206,286,294
Ensembl chr 1:205,956,342...206,282,575
JBrowse link
G Adam22 ADAM metallopeptidase domain 22 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM22 mRNA
panobinostat results in decreased expression of ADAM22 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:22,864,485...23,002,969
Ensembl chr 4:22,859,622...22,996,645
JBrowse link
G Adam28 ADAM metallopeptidase domain 28 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAM28 mRNA
panobinostat results in increased expression of ADAM28 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:50,356,745...50,425,911
Ensembl chr15:50,358,192...50,425,900
JBrowse link
G Adamts15 ADAM metallopeptidase with thrombospondin type 1 motif, 15 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA
panobinostat results in increased expression of ADAMTS15 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:31,977,001...32,000,378
Ensembl chr 8:31,977,001...32,000,378
JBrowse link
G Adamts17 ADAM metallopeptidase with thrombospondin type 1 motif, 17 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS17 mRNA CTD PMID:27188386 NCBI chr 1:127,802,872...128,126,764
Ensembl chr 1:127,802,978...128,124,171
JBrowse link
G Adamts19 ADAM metallopeptidase with thrombospondin type 1 motif, 19 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS19 mRNA
panobinostat results in increased expression of ADAMTS19 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:53,915,807...54,099,856
Ensembl chr18:53,915,807...54,099,120
JBrowse link
G Adcyap1 adenylate cyclase activating polypeptide 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of ADCYAP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:121,705,897...121,725,736
Ensembl chr 9:121,706,979...121,725,716
JBrowse link
G Adcyap1r1 ADCYAP receptor type I multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1R1 mRNA
panobinostat results in increased expression of ADCYAP1R1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:85,662,809...85,711,696
Ensembl chr 4:85,662,892...85,711,696
JBrowse link
G Adgrg1 adhesion G protein-coupled receptor G1 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA
panobinostat results in decreased expression of ADGRG1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:10,423,534...10,460,674
Ensembl chr19:10,423,501...10,460,674
JBrowse link
G Adgrg6 adhesion G protein-coupled receptor G6 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADGRG6 mRNA CTD PMID:27188386 NCBI chr 1:8,593,342...8,751,540
Ensembl chr 1:8,593,075...8,751,198
JBrowse link
G Adgrl3 adhesion G protein-coupled receptor L3 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of ADGRL3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:28,362,176...29,226,085
Ensembl chr14:28,393,394...28,967,980
JBrowse link
G Adgrv1 adhesion G protein-coupled receptor V1 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRV1 mRNA
panobinostat results in decreased expression of ADGRV1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:8,926,843...9,504,455
Ensembl chr 2:8,926,850...9,504,134
JBrowse link
G Adra2a adrenoceptor alpha 2A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADRA2A mRNA CTD PMID:27188386 NCBI chr 1:274,766,283...274,769,083
Ensembl chr 1:274,766,283...274,769,081
JBrowse link
G Afap1l1 actin filament associated protein 1-like 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of AFAP1L1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AFAP1L1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:57,052,659...57,114,589
Ensembl chr18:57,053,947...57,114,545
JBrowse link
G Ahnak AHNAK nucleoprotein increases expression
multiple interactions
ISO panobinostat results in increased expression of AHNAK mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AHNAK mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:225,184,883...225,429,638
Ensembl chr 1:225,184,939...225,215,015
JBrowse link
G Ajap1 adherens junctions associated protein 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AJAP1 mRNA
panobinostat results in increased expression of AJAP1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:170,615,885...170,679,315
Ensembl chr 5:170,615,886...170,679,315
JBrowse link
G Akap12 A-kinase anchoring protein 12 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AKAP12 mRNA
panobinostat results in decreased expression of AKAP12 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:40,816,130...40,906,582
Ensembl chr 1:40,816,107...40,906,581
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO [Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein CTD PMID:18445700 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Alcam activated leukocyte cell adhesion molecule increases expression
multiple interactions
ISO panobinostat results in increased expression of ALCAM mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALCAM mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:50,780,735...50,985,083
Ensembl chr11:50,781,127...50,985,083
JBrowse link
G Aldh1a2 aldehyde dehydrogenase 1 family, member A2 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of ALDH1A2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ALDH1A2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:77,640,234...77,719,488
Ensembl chr 8:77,640,222...77,719,489
JBrowse link
G Aldh1a3 aldehyde dehydrogenase 1 family, member A3 increases expression
multiple interactions
ISO panobinostat results in increased expression of ALDH1A3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1A3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:127,302,920...127,337,828
Ensembl chr 1:127,301,128...127,337,882
JBrowse link
G Aldh1l2 aldehyde dehydrogenase 1 family, member L2 increases expression
multiple interactions
ISO panobinostat results in increased expression of ALDH1L2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALDH1L2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:26,375,866...26,425,838
Ensembl chr 7:26,375,866...26,425,108
JBrowse link
G Alkal2 ALK and LTK ligand 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALKAL2 mRNA
panobinostat results in increased expression of ALKAL2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:49,824,725...49,834,921
Ensembl chr 6:49,825,469...49,834,912
JBrowse link
G Alx1 ALX homeobox 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of ALX1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ALX1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:44,751,865...44,771,458
Ensembl chr 7:44,751,873...44,771,458
JBrowse link
G Amer2 APC membrane recruitment protein 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of AMER2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMER2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:40,663,183...40,667,705
Ensembl chr15:40,665,041...40,667,173
JBrowse link
G Amigo2 adhesion molecule with Ig like domain 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AMIGO2 mRNA
panobinostat results in increased expression of AMIGO2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:138,704,124...138,707,221
Ensembl chr 7:138,704,126...138,707,221
JBrowse link
G Ang angiogenin multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANG mRNA CTD PMID:27188386 NCBI chr15:28,022,926...28,028,636 JBrowse link
G Angpt1 angiopoietin 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA
panobinostat results in increased expression of ANGPT1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:81,338,327...81,592,459
Ensembl chr 7:81,342,280...81,592,206
JBrowse link
G Angpt2 angiopoietin 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT2 mRNA
panobinostat results in increased expression of ANGPT2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr16:75,966,480...76,016,147
Ensembl chr16:75,966,352...76,016,195
JBrowse link
G Ankh ANKH inorganic pyrophosphate transport regulator multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKH mRNA
panobinostat results in increased expression of ANKH mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:80,131,563...80,256,948
Ensembl chr 2:80,131,563...80,256,954
JBrowse link
G Ankrd1 ankyrin repeat domain 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD1 mRNA
panobinostat results in increased expression of ANKRD1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:254,726,985...254,745,673
Ensembl chr 1:254,726,969...254,735,548
JBrowse link
G Ankrd22 ankyrin repeat domain 22 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANKRD22 mRNA CTD PMID:27188386 NCBI chr 1:252,430,750...252,461,346
Ensembl chr 1:252,429,677...252,461,461
JBrowse link
G Anks1b ankyrin repeat and sterile alpha motif domain containing 1B multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA CTD PMID:27188386 NCBI chr 7:30,507,135...31,684,604
Ensembl chr 7:30,699,476...31,681,182
JBrowse link
G Ano3 anoctamin 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA CTD PMID:27188386 NCBI chr 3:101,843,516...102,203,368
Ensembl chr 3:101,840,630...102,151,489
JBrowse link
G Anos1 anosmin 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANOS1 mRNA
panobinostat results in decreased expression of KAL1 mRNA
CTD PMID:26272509, PMID:27188386 Ensembl chr10:70,999,780...71,000,627 JBrowse link
G Anxa1 annexin A1 increases expression ISO panobinostat results in increased expression of ANXA1 mRNA CTD PMID:26272509 NCBI chr 1:237,893,983...237,910,002
Ensembl chr 1:237,893,966...237,910,012
JBrowse link
G Anxa2 annexin A2 increases expression
multiple interactions
ISO panobinostat results in increased expression of ANXA2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:75,687,134...75,723,589
Ensembl chr 8:75,687,100...75,723,594
JBrowse link
G Anxa3 annexin A3 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA3 mRNA
panobinostat results in increased expression of ANXA3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:14,371,921...14,426,503
Ensembl chr14:14,364,008...14,426,437
JBrowse link
G Anxa9 annexin A9 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA9 mRNA CTD PMID:27188386 NCBI chr 2:196,470,318...196,481,568
Ensembl chr 2:196,470,858...196,479,770
JBrowse link
G Aox1 aldehyde oxidase 1 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of AOX1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of AOX1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:64,929,682...65,007,872
Ensembl chr 9:64,929,721...65,007,870
JBrowse link
G Ap1m2 adaptor related protein complex 1 subunit mu 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AP1M2 mRNA
panobinostat results in increased expression of AP1M2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:22,318,941...22,336,827
Ensembl chr 8:22,319,331...22,336,794
JBrowse link
G Arap2 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of ARAP2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARAP2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:48,726,033...48,922,809
Ensembl chr14:48,726,045...48,922,983
JBrowse link
G Arfgef3 ARFGEF family member 3 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARFGEF3 mRNA
panobinostat results in decreased expression of ARFGEF3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:13,837,861...13,918,277
Ensembl chr 1:13,838,707...13,915,594
JBrowse link
G Arhgap15 Rho GTPase activating protein 15 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP15 mRNA
panobinostat results in decreased expression of ARHGAP15 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:28,626,987...29,236,225
Ensembl chr 3:28,627,084...29,236,219
JBrowse link
G Arhgap18 Rho GTPase activating protein 18 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP18 mRNA
panobinostat results in increased expression of ARHGAP18 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:19,227,115...19,463,139
Ensembl chr 1:19,227,121...19,376,301
JBrowse link
G Arhgap24 Rho GTPase activating protein 24 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP24 mRNA CTD PMID:27188386 NCBI chr14:8,383,211...8,600,526
Ensembl chr14:8,383,214...8,600,512
JBrowse link
G Arhgap31 Rho GTPase activating protein 31 multiple interactions
affects expression
ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ARHGAP31 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ARHGAP31 mRNA] CTD PMID:26733615 NCBI chr11:64,600,968...64,714,114
Ensembl chr11:64,601,029...64,714,252
JBrowse link
G Arhgap5 Rho GTPase activating protein 5 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of ARHGAP5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGAP5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:73,345,129...73,408,304
Ensembl chr 6:73,345,392...73,405,880
JBrowse link
G Arhgap6 Rho GTPase activating protein 6 increases expression
multiple interactions
ISO panobinostat results in increased expression of ARHGAP6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP6 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:26,314,561...26,845,242
Ensembl chr  X:26,315,878...26,376,467
JBrowse link
G Arid2 AT-rich interaction domain 2 affects expression
multiple interactions
ISO panobinostat affects the expression of ARID2 mRNA
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of ARID2 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of ARID2 mRNA]
CTD PMID:26733615 NCBI chr 7:137,680,564...137,798,329
Ensembl chr 7:137,680,530...137,795,655
JBrowse link
G Arid5b AT-rich interaction domain 5B multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARID5B mRNA
panobinostat results in increased expression of ARID5B mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr20:21,713,900...21,881,193
Ensembl chr20:21,564,975...21,880,715
JBrowse link
G Armh4 armadillo-like helical domain containing 4 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARMH4 mRNA
panobinostat results in decreased expression of ARMH4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:26,586,359...26,687,412
Ensembl chr15:26,587,179...26,678,420
JBrowse link
G Arnt2 aryl hydrocarbon receptor nuclear translocator 2 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of ARNT2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:146,399,217...146,556,437
Ensembl chr 1:146,399,217...146,556,171
JBrowse link
G Arntl2 aryl hydrocarbon receptor nuclear translocator-like 2 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of ARNTL2 mRNA CTD PMID:21791302 NCBI chr 4:181,103,774...181,158,415
Ensembl chr 4:181,103,774...181,214,994
JBrowse link
G Arrb1 arrestin, beta 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of ARRB1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139
JBrowse link
G Arx aristaless related homeobox decreases expression
multiple interactions
ISO panobinostat results in decreased expression of ARX mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARX mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:62,363,757...62,376,139
Ensembl chr  X:62,363,757...62,376,143
JBrowse link
G As3mt arsenite methyltransferase multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of AS3MT mRNA CTD PMID:21791302 NCBI chr 1:266,482,787...266,514,570
Ensembl chr 1:266,482,858...266,514,569
JBrowse link
G Asb9 ankyrin repeat and SOCS box-containing 9 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASB9 mRNA CTD PMID:27188386 NCBI chr  X:31,700,637...31,745,790
Ensembl chr  X:31,700,633...31,780,425
JBrowse link
G Ascl1 achaete-scute family bHLH transcription factor 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA CTD PMID:27188386 NCBI chr 7:28,038,662...28,040,504
Ensembl chr 7:28,038,662...28,040,510
JBrowse link
G Asic1 acid sensing ion channel subunit 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASIC1 mRNA CTD PMID:27188386 NCBI chr 7:141,324,714...141,354,937
Ensembl chr 7:141,326,321...141,354,937
JBrowse link
G Asns asparagine synthetase (glutamine-hydrolyzing) increases expression
multiple interactions
ISO panobinostat results in increased expression of ASNS mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASNS mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:33,742,876...33,761,106
Ensembl chr 4:33,743,364...33,761,163
JBrowse link
G Ass1 argininosuccinate synthase 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of ASS1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASS1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:10,327,411...10,375,847
Ensembl chr 3:10,327,414...10,375,826
JBrowse link
G Astn1 astrotactin 1 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of ASTN1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ASTN1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:76,054,965...76,370,674
Ensembl chr13:76,055,410...76,370,674
JBrowse link
G Astn2 astrotactin 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of ASTN2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASTN2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:81,179,614...82,168,528
Ensembl chr 5:81,179,605...82,168,427
JBrowse link
G Atf3 activating transcription factor 3 increases expression ISO panobinostat results in increased expression of ATF3 mRNA CTD PMID:26272509 NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
JBrowse link
G Atp13a4 ATPase 13A4 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP13A4 mRNA CTD PMID:27188386 NCBI chr11:74,833,824...74,968,160
Ensembl chr11:74,834,050...74,968,336
JBrowse link
G Atp23 ATP23 metallopeptidase and ATP synthase assembly factor homolog increases expression
multiple interactions
ISO panobinostat results in increased expression of ATP23 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP23 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:70,183,625...70,198,655
Ensembl chr 7:70,183,625...70,198,655
JBrowse link
G Atp2c2 ATPase secretory pathway Ca2+ transporting 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP2C2 mRNA
panobinostat results in increased expression of ATP2C2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:52,347,480...52,404,608
Ensembl chr19:52,347,580...52,404,607
JBrowse link
G Atp6v0a2 ATPase H+ transporting V0 subunit a2 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP6V0A2 mRNA
panobinostat results in decreased expression of ATP6V0A2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr12:37,368,321...37,398,233
Ensembl chr12:37,363,906...37,425,596
JBrowse link
G Atp6v0a4 ATPase H+ transporting V0 subunit a4 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0A4 mRNA
panobinostat results in increased expression of ATP6V0A4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:65,736,585...65,821,916
Ensembl chr 4:65,736,585...65,818,521
JBrowse link
G Atp6v0d2 ATPase H+ transporting V0 subunit D2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP6V0D2 mRNA
panobinostat results in increased expression of ATP6V0D2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:33,843,591...33,892,446
Ensembl chr 5:33,843,519...33,892,462
JBrowse link
G Atp8b1 ATPase phospholipid transporting 8B1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA
panobinostat results in increased expression of ATP8B1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:60,013,388...60,152,920
Ensembl chr18:60,013,382...60,095,354
JBrowse link
G Atp8b3 ATPase phospholipid transporting 8B3 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B3 mRNA
panobinostat results in increased expression of ATP8B3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:12,043,764...12,063,668
Ensembl chr 7:12,043,794...12,063,650
JBrowse link
G Atp9a ATPase phospholipid transporting 9A (putative) multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ATP9A mRNA
panobinostat results in decreased expression of ATP9A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:165,405,588...165,511,104
Ensembl chr 3:165,412,803...165,477,771
JBrowse link
G Axin2 axin 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AXIN2 mRNA
panobinostat results in increased expression of AXIN2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:97,212,483...97,238,824
Ensembl chr10:97,212,432...97,239,642
JBrowse link
G B3gnt7 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B3GNT7 mRNA
panobinostat results in increased expression of B3GNT7 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:93,326,283...93,330,234
Ensembl chr 9:93,326,283...93,330,233
JBrowse link
G Bace2 beta-secretase 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of BACE2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BACE2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:37,798,397...37,880,624
Ensembl chr11:37,798,370...37,880,821
JBrowse link
G Bag2 BAG cochaperone 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA
panobinostat results in increased expression of BAG2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:38,456,487...38,467,120
Ensembl chr 9:38,456,468...38,467,118
JBrowse link
G Bag5 BAG cochaperone 5 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of BAG5 mRNA CTD PMID:21791302 NCBI chr 6:136,180,640...136,185,651
Ensembl chr 6:136,182,006...136,185,651
JBrowse link
G Bambi BMP and activin membrane-bound inhibitor increases expression
multiple interactions
ISO panobinostat results in increased expression of BAMBI mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:56,905,419...56,909,675
Ensembl chr17:56,905,112...56,909,992
JBrowse link
G Batf3 basic leucine zipper ATF-like transcription factor 3 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of BATF3 mRNA CTD PMID:21791302 NCBI chr13:109,713,376...109,726,438
Ensembl chr13:109,713,489...109,724,863
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat] CTD PMID:18445700 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Baz1a bromodomain adjacent to zinc finger domain, 1A multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAZ1A mRNA
panobinostat results in increased expression of BAZ1A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:75,793,223...75,873,854
Ensembl chr 6:75,793,960...75,874,235
JBrowse link
G Bcl11a BAF chromatin remodeling complex subunit BCL11A increases expression
multiple interactions
ISO panobinostat results in increased expression of BCL11A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:108,826,717...108,921,197
Ensembl chr14:108,826,831...108,921,669
JBrowse link
G Bcl2 BCL2, apoptosis regulator affects expression
multiple interactions
decreases expression
ISO panobinostat affects the expression of BCL2 mRNA
(+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of BCL2 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA; [Panobinostat co-treated with (+)-JQ1 compound] results in decreased expression of BCL2 protein; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of BCL2 mRNA]
panobinostat results in decreased expression of BCL2 mRNA; panobinostat results in decreased expression of BCL2 protein
CTD PMID:24435446, PMID:26272509, PMID:26733615, PMID:27188386 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases expression
decreases expression
ISO (+)-JQ1 compound promotes the reaction [Panobinostat results in increased expression of BCL2L11 protein]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2L11 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound results in increased expression of BCL2L11 protein]
panobinostat results in increased expression of BCL2L11 protein
panobinostat results in decreased expression of BCL2L11 mRNA
CTD PMID:24435446, PMID:26272509, PMID:27188386 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Begain brain-enriched guanylate kinase-associated multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEGAIN mRNA
panobinostat results in decreased expression of BEGAIN mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:132,936,964...132,972,569
Ensembl chr 6:132,936,970...132,972,511
JBrowse link
G Best4 bestrophin 4 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BEST4 mRNA
panobinostat results in decreased expression of BEST4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:136,013,978...136,017,742
Ensembl chr 5:136,014,017...136,017,677
JBrowse link
G Bhlhe40 basic helix-loop-helix family, member e40 increases expression
multiple interactions
ISO panobinostat results in increased expression of BHLHE40 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BHLHE40 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:140,703,619...140,709,319
Ensembl chr 4:140,703,619...140,709,319
JBrowse link
G Bhlhe41 basic helix-loop-helix family, member e41 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of BHLHE41 mRNA CTD PMID:21791302 NCBI chr 4:180,230,742...180,235,138
Ensembl chr 4:180,232,382...180,234,804
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression ISO Panobinostat results in decreased expression of BIRC5 mRNA CTD PMID:30481203 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Bmp2 bone morphogenetic protein 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP2 mRNA
panobinostat results in increased expression of BMP2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318
JBrowse link
G Bmp4 bone morphogenetic protein 4 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP4 mRNA
panobinostat results in increased expression of BMP4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:20,776,060...20,791,013
Ensembl chr15:20,776,054...20,822,740
JBrowse link
G Bmp5 bone morphogenetic protein 5 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA
panobinostat results in increased expression of BMP5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:82,669,466...82,950,273
Ensembl chr 8:82,878,941...82,950,273
JBrowse link
G Bmp7 bone morphogenetic protein 7 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP7 mRNA
panobinostat results in increased expression of BMP7 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:170,879,972...170,955,820
Ensembl chr 3:170,879,973...170,955,399
JBrowse link
G Bmper BMP-binding endothelial regulator multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA
panobinostat results in increased expression of BMPER mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:24,369,916...24,615,484
Ensembl chr 8:24,369,916...24,615,479
JBrowse link
G Bmpr1b bone morphogenetic protein receptor type 1B multiple interactions
affects expression
ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of BMPR1B mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of BMPR1B mRNA] CTD PMID:26733615 NCBI chr 2:247,392,195...247,662,026
Ensembl chr 2:247,403,920...247,446,882
JBrowse link
G Bnc2 basonuclin 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of BNC2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:102,407,508...102,807,389
Ensembl chr 5:102,415,847...102,786,331
JBrowse link
G Bnipl BCL2 interacting protein like multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNIPL mRNA
panobinostat results in increased expression of BNIPL mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:196,415,736...196,425,727
Ensembl chr 2:196,415,738...196,425,727
JBrowse link
G Boc BOC cell adhesion associated, oncogene regulated multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BOC mRNA
panobinostat results in increased expression of BOC mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:61,084,216...61,159,220
Ensembl chr11:61,083,757...61,158,838
JBrowse link
G Bri3bp Bri3 binding protein increases expression ISO panobinostat results in increased expression of BRI3BP mRNA CTD PMID:26272509 NCBI chr12:36,576,018...36,587,839
Ensembl chr12:36,576,020...36,587,839
JBrowse link
G Brinp1 BMP/retinoic acid inducible neural specific 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of BRINP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BRINP1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:84,919,416...85,123,828
Ensembl chr 5:84,919,367...85,123,829
JBrowse link
G Brip1 BRCA1 interacting protein C-terminal helicase 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BRIP1 mRNA CTD PMID:27188386 NCBI chr10:73,507,009...73,632,742
Ensembl chr10:73,507,100...73,629,581
JBrowse link
G Bspry B-box and SPRY domain containing increases expression
multiple interactions
ISO panobinostat results in increased expression of BSPRY mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:78,334,284...78,356,462
Ensembl chr 5:78,334,284...78,356,460
JBrowse link
G C1galt1 core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C1GALT1 mRNA
panobinostat results in increased expression of C1GALT1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:33,890,353...33,943,219
Ensembl chr 4:33,890,349...33,943,211
JBrowse link
G C1qtnf4 C1q and TNF related 4 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C1QTNF4 mRNA
panobinostat results in decreased expression of C1QTNF4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:79,713,580...79,718,018
Ensembl chr 3:79,713,567...79,718,025
JBrowse link
G C2cd2 C2 calcium-dependent domain containing 2 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2CD2 mRNA
panobinostat results in decreased expression of C2CD2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:38,354,746...38,420,133
Ensembl chr11:38,357,424...38,420,119
JBrowse link
G C3 complement C3 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of C3 mRNA CTD PMID:21791302 NCBI chr 9:9,721,137...9,747,084
Ensembl chr 9:9,721,105...9,747,167
JBrowse link
G Ca12 carbonic anhydrase 12 increases expression
multiple interactions
ISO panobinostat results in increased expression of CA12 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA12 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:72,405,770...72,461,425
Ensembl chr 8:72,405,748...72,460,240
JBrowse link
G Ca13 carbonic anhydrase 13 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA13 mRNA CTD PMID:27188386 NCBI chr 2:88,282,961...88,314,254
Ensembl chr 2:88,282,961...88,314,254
JBrowse link
G Ca4 carbonic anhydrase 4 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of CA4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CA4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:72,272,286...72,281,069
Ensembl chr10:72,272,248...72,281,067
JBrowse link
G Ca8 carbonic anhydrase 8 increases expression
multiple interactions
ISO panobinostat results in increased expression of CA8 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CA8 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:21,249,018...21,345,810
Ensembl chr 5:21,249,020...21,345,810
JBrowse link
G Cacna2d1 calcium voltage-gated channel auxiliary subunit alpha2delta 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of CACNA2D1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CACNA2D1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:15,706,974...16,130,848
Ensembl chr 4:15,710,417...16,130,848
JBrowse link
G Cacnb2 calcium voltage-gated channel auxiliary subunit beta 2 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of CACNB2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CACNB2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:81,673,862...82,019,219
Ensembl chr17:81,798,756...82,017,682
JBrowse link
G Cadm4 cell adhesion molecule 4 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of CADM4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CADM4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:81,365,200...81,369,841
Ensembl chr 1:81,365,138...81,370,109
JBrowse link
G Calb2 calbindin 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of CALB2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALB2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:41,482,743...41,509,617
Ensembl chr19:41,482,728...41,509,658
JBrowse link
G Calca calcitonin-related polypeptide alpha increases expression
multiple interactions
ISO panobinostat results in increased expression of CALCA mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CALCA mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
JBrowse link
G Capn6 calpain 6 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of CAPN6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CAPN6 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:115,049,113...115,073,824
Ensembl chr  X:115,049,154...115,073,890
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [resveratrol co-treated with panobinostat] results in increased cleavage of CASP3 protein CTD PMID:22923501 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp8 caspase 8 multiple interactions
increases expression
ISO [Cisplatin co-treated with Panobinostat] affects the expression of CASP8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [Panobinostat co-treated with Vorinostat] results in increased cleavage of CASP8 protein; [Resveratrol co-treated with Panobinostat] results in increased cleavage of CASP8 protein; CASP8 protein affects the susceptibility to [Resveratrol co-treated with Panobinostat]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Resveratrol co-treated with Panobinostat] results in increased cleavage of CASP8 protein]
panobinostat results in increased expression of CASP8 mRNA
CTD PMID:21791302, PMID:22923501, PMID:26272509, PMID:27188386 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 multiple interactions ISO [resveratrol co-treated with panobinostat] results in increased cleavage of CASP9 protein CTD PMID:22923501 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cblc Cbl proto-oncogene C increases expression
multiple interactions
ISO panobinostat results in increased expression of CBLC mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CBLC mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:80,699,321...80,716,146
Ensembl chr 1:80,699,323...80,716,146
JBrowse link
G Cc2d2a coiled-coil and C2 domain containing 2A multiple interactions
affects expression
ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of CC2D2A mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of CC2D2A mRNA] CTD PMID:26733615 NCBI chr14:71,895,128...71,979,452
Ensembl chr14:71,895,246...71,973,419
JBrowse link
G Ccdc136 coiled-coil domain containing 136 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of CCDC136 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC136 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:56,674,737...56,704,501
Ensembl chr 4:56,674,832...56,704,549
JBrowse link
G Ccdc177 coiled-coil domain containing 177 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of CCDC177 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCDC177 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:104,403,617...104,410,991
Ensembl chr 6:104,406,897...104,409,005
JBrowse link
G Ccdc69 coiled-coil domain containing 69 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA
panobinostat results in increased expression of CCDC69 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:40,392,459...40,419,567
Ensembl chr10:40,392,460...40,419,054
JBrowse link
G Cckbr cholecystokinin B receptor decreases expression
multiple interactions
ISO panobinostat results in decreased expression of CCKBR mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:170,262,218...170,272,298
Ensembl chr 1:170,262,156...170,272,298
JBrowse link
G Ccl26 C-C motif chemokine ligand 26 increases expression
multiple interactions
ISO panobinostat results in increased expression of CCL26 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr12:24,157,182...24,161,870
Ensembl chr12:24,158,766...24,161,869
JBrowse link
G Ccn3 cellular communication network factor 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCN3 mRNA CTD PMID:27188386 NCBI chr 7:94,375,134...94,382,154
Ensembl chr 7:94,375,020...94,383,024
JBrowse link
G Ccng2 cyclin G2 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of CCNG2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNG2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:16,267,572...16,276,068
Ensembl chr14:16,267,573...16,276,068
JBrowse link
G Ccnt2 cyclin T2 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of CCNT2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCNT2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:44,475,959...44,516,892
Ensembl chr13:44,475,970...44,515,739
JBrowse link
G Cd200 Cd200 molecule multiple interactions
affects expression
ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of CD200 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of CD200 mRNA] CTD PMID:26733615 NCBI chr11:60,371,617...60,398,450
Ensembl chr11:60,371,684...60,403,196
JBrowse link
G Cd24 CD24 molecule multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA
panobinostat results in increased expression of CD24 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr20:48,335,540...48,340,847
Ensembl chr20:48,335,540...48,340,846
JBrowse link
G Cd44 CD44 molecule (Indian blood group) increases expression
multiple interactions
ISO panobinostat results in increased expression of CD44 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD44 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658
JBrowse link
G Cd52 CD52 molecule increases expression
multiple interactions
ISO panobinostat results in increased expression of CD52 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD52 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:152,322,910...152,324,469
Ensembl chr 5:152,322,916...152,324,469
JBrowse link
G Cd55 CD55 molecule (Cromer blood group) multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD55 mRNA
panobinostat results in increased expression of CD55 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:47,125,156...47,153,557
Ensembl chr13:47,126,741...47,154,292
JBrowse link
G Cd74 CD74 molecule multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD74 mRNA
panobinostat results in increased expression of CD74 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:56,071,420...56,080,851
Ensembl chr18:56,071,478...56,080,849
JBrowse link
G Cd9 CD9 molecule multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA
panobinostat results in increased expression of CD9 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:157,977,163...158,010,091
Ensembl chr 4:157,977,162...158,010,166
JBrowse link
G Cdc42ep3 CDC42 effector protein 3 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDC42EP3 mRNA
panobinostat results in decreased expression of CDC42EP3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:1,922,500...1,942,972
Ensembl chr 6:1,922,500...1,942,972
JBrowse link
G Cdc42ep5 CDC42 effector protein 5 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDC42EP5 mRNA
panobinostat results in increased expression of CDC42EP5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:73,717,207...73,719,600
Ensembl chr 1:73,719,005...73,719,529
JBrowse link
G Cdh1 cadherin 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA
panobinostat results in increased expression of CDH1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
JBrowse link
G Cdh10 cadherin 10 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH10 mRNA
panobinostat results in increased expression of CDH10 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:69,415,174...69,636,849
Ensembl chr 2:69,415,057...69,637,524
JBrowse link
G Cdh18 cadherin 18 increases expression
multiple interactions
ISO panobinostat results in increased expression of CDH18 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH18 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:73,651,408...74,693,342
Ensembl chr 2:74,360,622...74,693,341
JBrowse link
G Cdh2 cadherin 2 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH2 mRNA
panobinostat results in decreased expression of CDH2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:8,146,971...8,366,037
Ensembl chr18:8,146,971...8,360,684
JBrowse link
G Cdh3 cadherin 3 increases expression
multiple interactions
ISO panobinostat results in increased expression of CDH3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:38,668,957...38,719,801
Ensembl chr19:38,669,230...38,719,677
JBrowse link
G Cdh8 cadherin 8 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of CDH8 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDH8 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:6,031,654...6,431,502
Ensembl chr19:6,046,665...6,426,216
JBrowse link
G Cdk19 cyclin-dependent kinase 19 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CDK19 mRNA CTD PMID:27188386 NCBI chr20:45,458,499...45,598,799
Ensembl chr20:45,458,558...45,598,798
JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions
increases expression
ISO [(+)-JQ1 compound co-treated with Panobinostat] results in decreased expression of CDK6 protein; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDK6 mRNA
panobinostat results in increased expression of CDK6 mRNA
CTD PMID:24435446, PMID:26272509, PMID:27188386 NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression ISO panobinostat results in increased expression of CDKN1A protein CTD PMID:18445700 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B increases expression ISO panobinostat results in increased expression of CDKN1B protein CTD PMID:18445700 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Cdon cell adhesion associated, oncogene regulated increases expression
multiple interactions
ISO panobinostat results in increased expression of CDON mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDON mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:36,625,757...36,712,091
Ensembl chr 8:36,625,733...36,710,949
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPB mRNA
panobinostat results in increased expression of CEBPB mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
JBrowse link
G Cebpd CCAAT/enhancer binding protein delta increases expression
multiple interactions
ISO panobinostat results in increased expression of CEBPD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEBPD mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:89,008,008...89,009,146
Ensembl chr11:89,008,008...89,009,146
JBrowse link
G Celf5 CUGBP, Elav-like family member 5 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of CELF5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CELF5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:11,095,449...11,119,941
Ensembl chr 7:11,095,468...11,119,941
JBrowse link
G Cep85l centrosomal protein 85-like multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA
panobinostat results in increased expression of CEP85L mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr20:34,574,043...34,743,142
Ensembl chr20:34,575,950...34,684,418
JBrowse link
G Cfap91 cilia and flagella associated protein 91 decreases expression
multiple interactions
ISO Panobinostat results in decreased expression of CFAP91 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFAP91 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:64,975,499...65,019,169
Ensembl chr11:64,975,594...65,018,108
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CFLAR mRNA CTD PMID:27188386 NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
JBrowse link
G Cgnl1 cingulin-like 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of CGNL1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:78,126,670...78,278,490
Ensembl chr 8:78,126,675...78,233,430
JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 increases expression ISO panobinostat results in increased expression of CHAC1 mRNA CTD PMID:26272509 NCBI chr 3:111,160,205...111,163,425
Ensembl chr 3:111,160,205...111,163,425
JBrowse link
G Chga chromogranin A multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA
panobinostat results in increased expression of CHGA mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:126,434,226...126,445,569
Ensembl chr 6:126,434,226...126,445,568
JBrowse link
G Chodl chondrolectin multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA
panobinostat results in increased expression of CHODL mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:17,537,980...17,560,305
Ensembl chr11:17,538,063...17,560,296
JBrowse link
G Chrm3 cholinergic receptor, muscarinic 3 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA
panobinostat results in increased expression of CHRM3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:63,990,599...64,463,222
Ensembl chr17:63,990,599...63,994,169
JBrowse link
G Chrna3 cholinergic receptor nicotinic alpha 3 subunit multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA CTD PMID:27188386 NCBI chr 8:59,594,007...59,607,122
Ensembl chr 8:59,592,403...59,607,275
JBrowse link
G Chst15 carbohydrate sulfotransferase 15 increases expression
multiple interactions
ISO panobinostat results in increased expression of CHST15 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST15 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:204,243,396...204,328,960
Ensembl chr 1:204,245,645...204,322,544
JBrowse link
G Chst4 carbohydrate sulfotransferase 4 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHST4 mRNA
panobinostat results in increased expression of CHST4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:41,630,060...41,642,373
Ensembl chr19:41,631,715...41,640,367
JBrowse link
G Chsy1 chondroitin sulfate synthase 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHSY1 mRNA
panobinostat results in increased expression of CHSY1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:127,010,587...127,071,570
Ensembl chr 1:127,010,588...127,071,570
JBrowse link
G Cited2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CITED2 mRNA
panobinostat results in increased expression of CITED2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:12,823,363...12,825,806
Ensembl chr 1:12,823,363...12,825,786
JBrowse link
G Cldn1 claudin 1 increases expression ISO panobinostat results in increased expression of CLDN1 mRNA CTD PMID:26272509 NCBI chr11:77,815,216...77,830,373
Ensembl chr11:77,815,181...77,830,416
JBrowse link
G Cldn23 claudin 23 increases expression
multiple interactions
ISO panobinostat results in increased expression of CLDN23 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN23 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr16:59,988,603...59,990,327
Ensembl chr16:59,988,603...59,990,326
JBrowse link
G Cldn4 claudin 4 increases expression
multiple interactions
ISO panobinostat results in increased expression of CLDN4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr12:24,761,210...24,763,008
Ensembl chr12:24,761,210...24,763,005
JBrowse link
G Cldn6 claudin 6 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN6 mRNA
panobinostat results in increased expression of CLDN6 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:12,999,256...13,002,860
Ensembl chr10:13,000,090...13,002,862
JBrowse link
G Cldn7 claudin 7 increases expression
multiple interactions
ISO panobinostat results in increased expression of CLDN7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:56,576,326...56,578,632
Ensembl chr10:56,576,428...56,578,626
JBrowse link
G Clgn calmegin decreases expression
multiple interactions
ISO panobinostat results in decreased expression of CLGN mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLGN mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:24,545,257...24,578,527
Ensembl chr19:24,545,318...24,576,798
JBrowse link
G Clic6 chloride intracellular channel 6 increases expression
multiple interactions
ISO panobinostat results in increased expression of CLIC6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLIC6 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:32,655,653...32,698,004
Ensembl chr11:32,655,616...32,699,382
JBrowse link
G Clp1 cleavage factor polyribonucleotide kinase subunit 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLP1 mRNA CTD PMID:27188386 NCBI chr 3:72,125,269...72,137,122
Ensembl chr 3:72,125,273...72,128,973
JBrowse link
G Clstn2 calsyntenin 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLSTN2 mRNA
panobinostat results in increased expression of CLSTN2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:105,322,577...106,036,821
Ensembl chr 8:105,323,837...105,462,168
JBrowse link
G Cltrn collectrin, amino acid transport regulator multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CLTRN mRNA
panobinostat results in decreased expression of CLTRN mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:32,118,082...32,153,687
Ensembl chr  X:32,118,054...32,153,794
JBrowse link
G Clu clusterin increases expression
multiple interactions
ISO panobinostat results in increased expression of CLU mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLU mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857
JBrowse link
G Cnksr2 connector enhancer of kinase suppressor of Ras 2 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of CNKSR2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:39,711,001...39,953,860
Ensembl chr  X:39,711,201...39,951,847
JBrowse link
G Cnmd chondromodulin increases expression
multiple interactions
ISO panobinostat results in increased expression of CNMD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:61,923,291...61,947,840
Ensembl chr15:61,923,299...61,947,764
JBrowse link
G Cnot4 CCR4-NOT transcription complex, subunit 4 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNOT4 mRNA CTD PMID:27188386 NCBI chr 4:62,561,443...62,663,225
Ensembl chr 4:62,561,444...62,663,200
JBrowse link
G Cnrip1 cannabinoid receptor interacting protein 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNRIP1 mRNA
panobinostat results in increased expression of CNRIP1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:100,217,547...100,247,235
Ensembl chr14:100,217,289...100,247,235
JBrowse link
G Cntn1 contactin 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA
panobinostat results in increased expression of CNTN1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:133,290,606...133,588,314
Ensembl chr 7:133,400,485...133,586,677
JBrowse link
G Cntn2 contactin 2 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of CNTN2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:49,280,913...49,314,061
Ensembl chr13:49,285,310...49,313,940
JBrowse link
G Cobl cordon-bleu WH2 repeat protein multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA
panobinostat results in increased expression of COBL mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:92,341,949...92,497,169
Ensembl chr14:92,342,957...92,577,936
JBrowse link
G Cobll1 cordon-bleu WH2 repeat protein-like 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBLL1 mRNA
panobinostat results in increased expression of COBLL1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:51,137,104...51,298,956
Ensembl chr 3:51,137,076...51,297,852
JBrowse link
G Col11a1 collagen type XI alpha 1 chain increases expression ISO panobinostat results in increased expression of COL11A1 mRNA CTD PMID:27188386 NCBI chr 2:216,863,423...217,056,523
Ensembl chr 2:216,863,428...217,056,523
JBrowse link
G Col14a1 collagen type XIV alpha 1 chain multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL14A1 mRNA
panobinostat results in increased expression of COL14A1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:95,054,877...95,274,073
Ensembl chr 7:95,074,236...95,273,298
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A1 mRNA CTD PMID:27188386 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
JBrowse link
G Col1a2 collagen type I alpha 2 chain multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA
panobinostat results in increased expression of COL1A2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151
JBrowse link
G Col23a1 collagen type XXIII alpha 1 chain increases expression
multiple interactions
ISO panobinostat results in increased expression of COL23A1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL23A1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:34,846,618...34,934,991
Ensembl chr10:34,903,343...34,933,539
JBrowse link
G Col5a2 collagen type V alpha 2 chain increases expression ISO panobinostat results in increased expression of COL5A2 mRNA CTD PMID:26272509 NCBI chr 9:52,091,088...52,238,735
Ensembl chr 9:52,092,511...52,238,564
JBrowse link
G Col5a3 collagen type V alpha 3 chain multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL5A3 mRNA
panobinostat results in increased expression of COL5A3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:21,786,324...21,831,751
Ensembl chr 8:21,786,324...21,831,668
JBrowse link
G Col6a1 collagen type VI alpha 1 chain multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A1 mRNA
panobinostat results in increased expression of COL6A1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr20:12,657,913...12,676,370
Ensembl chr20:12,658,065...12,675,561
JBrowse link
G Col6a3 collagen type VI alpha 3 chain multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL6A3 mRNA
panobinostat results in increased expression of COL6A3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:97,926,784...98,004,643
Ensembl chr 9:97,926,787...98,004,546
JBrowse link
G Col9a3 collagen type IX alpha 3 chain multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL9A3 mRNA
panobinostat results in increased expression of COL9A3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:176,102,287...176,124,839
Ensembl chr 3:176,102,351...176,124,306
JBrowse link
G Colec12 collectin sub-family member 12 increases expression
multiple interactions
ISO panobinostat results in increased expression of COLEC12 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COLEC12 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:867,048...1,054,047
Ensembl chr18:867,048...1,052,606
JBrowse link
G Colgalt2 collagen beta(1-O)galactosyltransferase 2 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of COLGALT2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:69,797,558...69,902,916
Ensembl chr13:69,797,880...69,901,170
JBrowse link
G Comtd1 catechol-O-methyltransferase domain containing 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of COMTD1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:2,631,529...2,634,640
Ensembl chr15:2,631,529...2,634,640
JBrowse link
G Coro2a coronin 2A increases expression
multiple interactions
ISO panobinostat results in increased expression of CORO2A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CORO2A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:62,154,526...62,210,797
Ensembl chr 5:62,156,839...62,187,930
JBrowse link
G Cpe carboxypeptidase E increases expression
multiple interactions
ISO panobinostat results in increased expression of CPE mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPE mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr16:26,906,716...27,014,811
Ensembl chr16:26,906,716...27,014,813
JBrowse link
G Cped1 cadherin-like and PC-esterase domain containing 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of CPED1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPED1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:49,055,988...49,333,729
Ensembl chr 4:49,056,010...49,333,304
JBrowse link
G Cpne4 copine 4 increases expression
multiple interactions
ISO panobinostat results in increased expression of CPNE4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:113,105,814...113,586,429
Ensembl chr 8:113,105,814...113,586,418
JBrowse link
G Cpxm2 carboxypeptidase X (M14 family), member 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of CPXM2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPXM2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:204,048,785...204,161,090
Ensembl chr 1:204,048,785...204,087,001
JBrowse link
G Cr1l complement C3b/C4b receptor 1 like increases expression
multiple interactions
ISO panobinostat results in increased expression of CR1L mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:113,824,886...113,872,097
Ensembl chr13:113,824,892...113,872,097
JBrowse link
G Cr2 complement C3d receptor 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of CR2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:113,890,274...113,927,824
Ensembl chr13:113,890,272...113,927,877
JBrowse link
G Crabp1 cellular retinoic acid binding protein 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP1 mRNA CTD PMID:27188386 NCBI chr 8:59,344,097...59,352,135
Ensembl chr 8:59,344,083...59,352,132
JBrowse link
G Crabp2 cellular retinoic acid binding protein 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRABP2 mRNA
panobinostat results in increased expression of CRABP2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:187,322,416...187,326,794
Ensembl chr 2:184,882,969...184,883,505
JBrowse link
G Crip1 cysteine rich protein 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA CTD PMID:27188386 NCBI chr 6:137,959,171...137,967,042
Ensembl chr 6:137,959,171...137,967,042
JBrowse link
G Crispld1 cysteine-rich secretory protein LCCL domain containing 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of CRISPLD1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRISPLD1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:663,750...711,033
Ensembl chr 5:670,754...711,033
JBrowse link
G Cryba1 crystallin, beta A1 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA1 mRNA
panobinostat results in decreased expression of CRYBA1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:65,160,777...65,167,504
Ensembl chr10:65,161,152...65,167,494
JBrowse link
G Cryba4 crystallin, beta A4 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of CRYBA4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr12:50,407,843...50,414,434
Ensembl chr12:50,407,843...50,414,432
JBrowse link
G Crybg1 crystallin beta-gamma domain containing 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA
panobinostat results in increased expression of CRYBG1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr20:48,927,942...49,123,724
Ensembl chr20:48,927,914...48,969,499
JBrowse link
G Csf2ra colony stimulating factor 2 receptor subunit alpha multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSF2RA mRNA CTD PMID:27188386 NCBI chr14:1,462,292...1,467,264
Ensembl chr14:1,462,358...1,467,264
JBrowse link
G Cspg5 chondroitin sulfate proteoglycan 5 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSPG5 mRNA
panobinostat results in decreased expression of CSPG5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:118,333,695...118,348,040
Ensembl chr 8:118,333,706...118,347,582
JBrowse link
G Csrnp3 cysteine and serine rich nuclear protein 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CSRNP3 mRNA CTD PMID:27188386 NCBI chr 3:51,883,559...52,120,290
Ensembl chr 3:51,883,559...52,120,290
JBrowse link
G Cthrc1 collagen triple helix repeat containing 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA CTD PMID:27188386 NCBI chr 7:77,966,722...77,977,004
Ensembl chr 7:77,966,722...77,977,004
JBrowse link
G Ctnnd2 catenin delta 2 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA
panobinostat results in decreased expression of CTNND2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:83,227,247...84,094,315
Ensembl chr 2:83,393,282...84,094,315
JBrowse link
G Cul3 cullin 3 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of CUL3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CUL3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:86,044,485...86,129,066
Ensembl chr 9:86,044,485...86,129,329
JBrowse link
G Cx3cl1 C-X3-C motif chemokine ligand 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CX3CL1 mRNA
panobinostat results in increased expression of CX3CL1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:10,644,267...10,654,861
Ensembl chr19:10,644,244...10,653,800
JBrowse link
G Cxcl12 C-X-C motif chemokine ligand 12 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA
panobinostat results in increased expression of CXCL12 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
JBrowse link
G Cxcl14 C-X-C motif chemokine ligand 14 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL14 mRNA
panobinostat results in increased expression of CXCL14 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:9,109,731...9,117,754
Ensembl chr17:9,109,731...9,117,750
JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of CXCR4 mRNA CTD PMID:21791302 NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
JBrowse link
G Cxxc5 CXXC finger protein 5 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXXC5 mRNA
panobinostat results in increased expression of CXXC5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:28,626,386...28,656,916
Ensembl chr18:28,653,592...28,656,937
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1A1 mRNA
panobinostat results in increased expression of CYP1A1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of CYP1B1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYP1B1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
JBrowse link
G Cyren cell cycle regulator of NHEJ decreases expression ISO panobinostat results in decreased expression of CYREN mRNA CTD PMID:26272509 NCBI chr 4:62,391,770...62,397,162
Ensembl chr 4:62,391,770...62,396,035
JBrowse link
G Cyria CYFIP related Rac1 interactor A multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CYRIA mRNA
Panobinostat results in increased expression of CYRIA mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:37,555,167...37,661,196
Ensembl chr 6:37,555,182...37,665,064
JBrowse link
G Dab1 DAB adaptor protein 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAB1 mRNA
panobinostat results in decreased expression of DAB1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:123,154,360...124,279,170
Ensembl chr 5:123,905,166...124,280,115
JBrowse link
G Dach2 dachshund family transcription factor 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of DACH2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACH2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:84,924,570...85,484,150
Ensembl chr  X:85,338,928...85,483,719
JBrowse link
G Dact1 dishevelled-binding antagonist of beta-catenin 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA
panobinostat results in increased expression of DACT1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:93,740,440...93,751,003
Ensembl chr 6:93,740,586...93,749,809
JBrowse link
G Dazl deleted in azoospermia-like multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA
panobinostat results in decreased expression of DAZL mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:12,633,983...12,651,017
Ensembl chr 9:12,633,990...12,650,938
JBrowse link
G Dcaf12l2 DDB1 and CUL4 associated factor 12-like 2 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCAF12L2 mRNA
panobinostat results in decreased expression of DCAF12L2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:130,823,651...130,825,369
Ensembl chr  X:130,823,866...130,825,305
JBrowse link
G Dcaf4 DDB1 and CUL4 associated factor 4 increases expression
multiple interactions
ISO panobinostat results in increased expression of DCAF4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCAF4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:107,001,763...107,027,466
Ensembl chr 6:107,001,763...107,027,456
JBrowse link
G Dcc DCC netrin 1 receptor multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA
panobinostat results in increased expression of DCC mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:66,518,213...67,629,801
Ensembl chr18:66,523,120...67,224,566
JBrowse link
G Dclk1 doublecortin-like kinase 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCLK1 mRNA
panobinostat results in increased expression of DCLK1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:144,646,255...144,939,389
Ensembl chr 2:144,646,308...144,936,927
JBrowse link
G Dclk2 doublecortin-like kinase 2 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCLK2 mRNA
panobinostat results in decreased expression of DCLK2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:186,116,624...186,245,937
Ensembl chr 2:186,116,624...186,245,771
JBrowse link
G Dcun1d4 defective in cullin neddylation 1 domain containing 4 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DCUN1D4 mRNA CTD PMID:27188386 NCBI chr14:37,210,721...37,294,517
Ensembl chr14:37,210,721...37,294,472
JBrowse link
G Dennd1a DENN domain containing 1A multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA
panobinostat results in decreased expression of DENND1A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:22,061,120...22,501,502
Ensembl chr 3:22,058,400...22,500,765
JBrowse link
G Dennd1b DENN domain containing 1B multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1B mRNA
panobinostat results in decreased expression of DENND1B mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:56,015,813...56,242,041
Ensembl chr13:56,015,901...56,236,677
JBrowse link
G Dennd2a DENN domain containing 2A multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND2A mRNA
panobinostat results in decreased expression of DENND2A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:67,242,257...67,342,993
Ensembl chr 4:67,242,271...67,301,102
JBrowse link
G Dennd4a DENN domain containing 4A multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DENND4A mRNA
panobinostat results in increased expression of DENND4A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:70,293,355...70,406,675
Ensembl chr 8:70,317,586...70,406,751
JBrowse link
G Depdc1b DEP domain containing 1B decreases expression ISO panobinostat results in decreased expression of DEPDC1B mRNA CTD PMID:26272509 NCBI chr 2:39,980,796...40,069,982
Ensembl chr 2:40,000,313...40,069,975
JBrowse link
G Depdc7 DEP domain containing 7 increases expression
multiple interactions
ISO panobinostat results in increased expression of DEPDC7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:94,665,714...94,687,013
Ensembl chr 3:94,665,717...94,686,989
JBrowse link
G Deptor DEP domain containing MTOR-interacting protein increases expression
multiple interactions
ISO panobinostat results in increased expression of DEPTOR mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:94,795,161...95,000,750
Ensembl chr 7:94,795,214...94,995,809
JBrowse link
G Dhrs3 dehydrogenase/reductase 3 increases expression
multiple interactions
ISO panobinostat results in increased expression of DHRS3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:162,809,090...162,843,385
Ensembl chr 5:162,808,646...162,843,383
JBrowse link
G Diaph2 diaphanous-related formin 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of DIAPH2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:99,722,910...100,363,228 JBrowse link
G Dipk1c divergent protein kinase domain 1C decreases expression
multiple interactions
ISO panobinostat results in decreased expression of DIPK1C mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DIPK1C mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:81,569,693...81,591,683
Ensembl chr18:81,569,910...81,590,887
JBrowse link
G Dlc1 DLC1 Rho GTPase activating protein increases expression
multiple interactions
ISO panobinostat results in increased expression of DLC1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLC1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr16:58,776,489...59,247,752
Ensembl chr16:59,077,574...59,247,754
JBrowse link
G Dlk1 delta like non-canonical Notch ligand 1 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of DLK1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DLK1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:133,576,513...133,583,751
Ensembl chr 6:133,552,821...133,583,751
JBrowse link
G Dlx3 distal-less homeobox 3 increases expression
multiple interactions
ISO panobinostat results in increased expression of DLX3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DLX3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:82,937,971...82,943,367
Ensembl chr10:82,937,971...82,943,348
JBrowse link
G Dlx6 distal-less homeobox 6 decreases expression ISO panobinostat results in decreased expression of DLX6 mRNA CTD PMID:26272509 NCBI chr 4:32,373,096...32,377,388
Ensembl chr 4:32,373,641...32,377,253
JBrowse link
G Dmrta2 DMRT-like family A2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DMRTA2 mRNA
panobinostat results in increased expression of DMRTA2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:129,754,295...129,760,045
Ensembl chr 5:129,756,149...129,758,986
JBrowse link
G Dner delta/notch-like EGF repeat containing multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA CTD PMID:27188386 NCBI chr 9:91,965,866...92,291,172
Ensembl chr 9:91,965,866...92,291,220
JBrowse link
G Dock5 dedicator of cytokinesis 5 increases expression
multiple interactions
ISO panobinostat results in increased expression of DOCK5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:44,449,108...44,627,774
Ensembl chr15:44,453,308...44,627,765
JBrowse link
G Dock9 dedicator of cytokinesis 9 increases expression
multiple interactions
ISO panobinostat results in increased expression of DOCK9 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOCK9 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:107,945,664...108,210,967
Ensembl chr15:107,945,664...108,210,826
JBrowse link
G Dok5 docking protein 5 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DOK5 mRNA CTD PMID:27188386 NCBI chr 3:168,345,116...168,482,445
Ensembl chr 3:168,345,152...168,482,441
JBrowse link
G Dppa5 developmental pluripotency associated 5 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA
panobinostat results in increased expression of DPPA5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:85,711,560...85,713,313
Ensembl chr 8:85,711,795...85,712,647
Ensembl chr 7:85,711,795...85,712,647
Ensembl chr 3:85,711,795...85,712,647
JBrowse link
G Dsc2 desmocollin 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of DSC2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DSC2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:11,826,705...11,858,801
Ensembl chr18:11,826,706...11,858,754
JBrowse link
G Dst dystonin decreases expression
multiple interactions
ISO panobinostat results in decreased expression of DST mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DST mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:37,902,336...38,296,961
Ensembl chr 9:37,902,303...38,196,273
JBrowse link
G Dusp10 dual specificity phosphatase 10 increases expression
multiple interactions
ISO panobinostat results in increased expression of DUSP10 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP10 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:104,284,660...104,321,455
Ensembl chr13:104,284,660...104,321,455
JBrowse link
G Dusp23 dual specificity phosphatase 23 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of DUSP23 mRNA CTD PMID:21791302 NCBI chr13:91,018,670...91,019,862
Ensembl chr13:91,018,510...91,020,112
JBrowse link
G Dusp4 dual specificity phosphatase 4 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of DUSP4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DUSP4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr16:61,080,767...61,090,973
Ensembl chr16:61,078,175...61,091,169
JBrowse link
G Dusp5 dual specificity phosphatase 5 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DUSP5 mRNA
panobinostat results in increased expression of DUSP5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:274,245,184...274,258,595
Ensembl chr 1:274,245,184...274,258,595
JBrowse link
G Dync1i1 dynein cytoplasmic 1 intermediate chain 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DYNC1I1 mRNA
panobinostat results in increased expression of DYNC1I1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:30,807,755...31,121,097
Ensembl chr 4:30,807,879...31,121,090
JBrowse link
G E2f2 E2F transcription factor 2 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of E2F2 mRNA
panobinostat results in decreased expression of E2F2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:154,516,611...154,540,228
Ensembl chr 5:154,522,119...154,540,265
JBrowse link
G Ebf1 EBF transcription factor 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBF1 mRNA
panobinostat results in increased expression of EBF1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:23,654,849...24,051,627
Ensembl chr10:23,661,013...24,050,209
JBrowse link
G Ebi3 Epstein-Barr virus induced 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EBI3 mRNA CTD PMID:27188386 NCBI chr 9:11,110,874...11,114,843
Ensembl chr 9:11,110,874...11,114,843
JBrowse link
G Ecpas Ecm29 proteasome adaptor and scaffold multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ECPAS mRNA
panobinostat results in decreased expression of ECPAS mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:75,928,510...76,040,771
Ensembl chr 5:75,931,293...76,039,760
JBrowse link
G Edn1 endothelin 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of EDN1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
JBrowse link
G Ednra endothelin receptor type A increases expression
multiple interactions
ISO panobinostat results in increased expression of EDNRA mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:33,928,356...33,991,703
Ensembl chr19:33,928,356...33,991,703
JBrowse link
G Ednrb endothelin receptor type B multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA
panobinostat results in increased expression of EDNRB mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:88,004,775...88,036,354
Ensembl chr15:88,006,977...88,036,354
JBrowse link
G Efna1 ephrin A1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA
panobinostat results in increased expression of EFNA1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:188,588,808...188,596,156
Ensembl chr 2:188,588,796...188,596,222
JBrowse link
G Efna5 ephrin A5 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EFNA5 mRNA
panobinostat results in decreased expression of EFNA5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:110,054,002...110,329,878
Ensembl chr 9:110,057,155...110,225,486
JBrowse link
G Egf epidermal growth factor decreases expression
multiple interactions
ISO panobinostat results in decreased expression of EGF mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egfl8 EGF-like-domain, multiple 8 increases expression ISO panobinostat results in increased expression of EGFL8 mRNA CTD PMID:26272509 NCBI chr20:4,378,205...4,380,959
Ensembl chr20:4,378,206...4,380,600
JBrowse link
G Eif3m eukaryotic translation initiation factor 3, subunit M decreases expression ISO panobinostat results in decreased expression of EIF3M mRNA CTD PMID:26272509 NCBI chr 3:94,990,086...95,007,690
Ensembl chr 3:94,990,068...95,007,712
JBrowse link
G Eif4e3 eukaryotic translation initiation factor 4E family member 3 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of EIF4E3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EIF4E3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:132,068,581...132,111,092
Ensembl chr 4:132,068,598...132,111,079
JBrowse link
G Elf1 E74 like ETS transcription factor 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of ELF1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:61,772,544...61,868,442
Ensembl chr15:61,826,711...61,868,343
JBrowse link
G Elf3 E74 like ETS transcription factor 3 increases expression
multiple interactions
ISO panobinostat results in increased expression of ELF3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:52,083,873...52,088,798
Ensembl chr13:52,083,859...52,088,780
JBrowse link
G Elf5 E74 like ETS transcription factor 5 increases expression
multiple interactions
ISO panobinostat results in increased expression of ELF5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELF5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:93,333,514...93,374,454
Ensembl chr 3:93,351,619...93,371,656
JBrowse link
G Elk3 ETS transcription factor ELK3 increases expression
multiple interactions
ISO panobinostat results in increased expression of ELK3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELK3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:34,086,213...34,149,601
Ensembl chr 7:34,086,220...34,121,694
JBrowse link
G Elmod1 ELMO domain containing 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of ELMOD1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:58,486,078...58,542,884
Ensembl chr 8:58,486,078...58,542,844
JBrowse link
G Elovl2 ELOVL fatty acid elongase 2 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of ELOVL2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:21,382,461...21,422,413
Ensembl chr17:21,382,455...21,422,407
JBrowse link
G Elp4 elongator acetyltransferase complex subunit 4 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of ELP4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELP4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:95,733,810...95,954,987 JBrowse link
G Emilin3 elastin microfibril interfacer 3 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of EMILIN3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EMILIN3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:156,899,892...156,906,566
Ensembl chr 3:156,901,077...156,905,892
JBrowse link
G Emp1 epithelial membrane protein 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of EMP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EMP1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:169,161,076...169,181,967
Ensembl chr 4:169,147,243...169,181,966
JBrowse link
G Enox1 ecto-NOX disulfide-thiol exchanger 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENOX1 mRNA CTD PMID:27188386 NCBI chr15:59,331,134...59,884,512
Ensembl chr15:59,678,165...59,884,511
JBrowse link
G Enpp2 ectonucleotide pyrophosphatase/phosphodiesterase 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ENPP2 mRNA
panobinostat results in increased expression of ENPP2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:94,479,931...94,563,086
Ensembl chr 7:94,480,396...94,563,001
JBrowse link
G Eogt EGF domain specific O-linked N-acetylglucosamine transferase multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EOGT mRNA
panobinostat results in increased expression of EOGT mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:129,477,779...129,515,435
Ensembl chr 4:129,477,807...129,515,435
JBrowse link
G Epas1 endothelial PAS domain protein 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of EPAS1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPAS1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:10,306,508...10,385,239
Ensembl chr 6:10,306,405...10,387,265
JBrowse link
G Epb41l3 erythrocyte membrane protein band 4.1-like 3 increases expression
multiple interactions
ISO panobinostat results in increased expression of EPB41L3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:117,314,935...117,666,408
Ensembl chr 9:117,538,009...117,666,410
JBrowse link
G Epb41l5 erythrocyte membrane protein band 4.1 like 5 increases expression
multiple interactions
ISO panobinostat results in increased expression of EPB41L5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:35,622,472...35,673,449
Ensembl chr13:35,580,098...35,668,968
JBrowse link
G Epcam epithelial cell adhesion molecule multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPCAM mRNA
panobinostat results in increased expression of EPCAM mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:11,282,194...11,308,870
Ensembl chr 6:11,281,964...11,298,216
JBrowse link
G Epha1 Eph receptor A1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA CTD PMID:27188386 NCBI chr 4:71,749,100...71,763,681
Ensembl chr 4:71,749,242...71,763,679
JBrowse link
G Epha3 Eph receptor A3 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA3 mRNA
panobinostat results in increased expression of EPHA3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:421,253...783,037
Ensembl chr11:421,135...782,954
JBrowse link
G Epha4 Eph receptor A4 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHA4 mRNA
panobinostat results in decreased expression of EPHA4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:83,111,222...83,253,486
Ensembl chr 9:83,111,222...83,253,458
JBrowse link
G Epha7 Eph receptor A7 increases expression
multiple interactions
ISO panobinostat results in increased expression of EPHA7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA7 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:43,602,744...43,761,198
Ensembl chr 5:43,603,043...43,757,549
JBrowse link
G Ephb2 Eph receptor B2 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of EPHB2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:155,024,478...155,143,539
Ensembl chr 5:155,022,493...155,204,456
JBrowse link
G Epn3 epsin 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPN3 mRNA CTD PMID:27188386 NCBI chr10:82,220,762...82,231,200
Ensembl chr10:82,220,762...82,229,140
JBrowse link
G Eps8l2 EPS8-like 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPS8L2 mRNA CTD PMID:27188386 NCBI chr 1:214,327,992...214,353,466
Ensembl chr 1:214,328,071...214,353,461
JBrowse link
G Epsti1 epithelial stromal interaction 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPSTI1 mRNA
panobinostat results in increased expression of EPSTI1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:60,084,966...60,190,360
Ensembl chr15:60,084,918...60,190,363
JBrowse link
G Erap1 endoplasmic reticulum aminopeptidase 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ERAP1 mRNA
panobinostat results in decreased expression of ERAP1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:1,410,877...1,449,734
Ensembl chr 2:1,410,934...1,449,733
JBrowse link
G Erbb3 erb-b2 receptor tyrosine kinase 3 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA
panobinostat results in increased expression of ERBB3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:2,989,202...3,010,610
Ensembl chr 7:2,989,340...3,010,350
JBrowse link
G Erp27 endoplasmic reticulum protein 27 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERP27 mRNA
panobinostat results in increased expression of ERP27 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:170,893,946...170,912,629
Ensembl chr 4:170,893,946...170,912,629
JBrowse link
G Esrp1 epithelial splicing regulatory protein 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of ESRP1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:24,576,988...24,631,758
Ensembl chr 5:24,576,991...24,631,698
JBrowse link
G Esrp2 epithelial splicing regulatory protein 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRP2 mRNA
panobinostat results in increased expression of ESRP2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:38,113,412...38,120,578
Ensembl chr19:38,113,412...38,120,578
JBrowse link
G Etnk1 ethanolamine kinase 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of ETNK1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETNK1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:177,402,904...177,447,047
Ensembl chr 4:177,402,904...177,447,028
JBrowse link
G Ets1 ETS proto-oncogene 1, transcription factor increases expression
multiple interactions
ISO panobinostat results in increased expression of ETS1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:33,756,634...33,879,625
Ensembl chr 8:33,816,386...33,879,625
JBrowse link
G Etv1 ETS variant transcription factor 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ETV1 mRNA
panobinostat results in decreased expression of ETV1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:58,467,215...58,558,640
Ensembl chr 6:58,467,254...58,558,631
JBrowse link
G Ext1 exostosin glycosyltransferase 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EXT1 mRNA
panobinostat results in decreased expression of EXT1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:92,605,008...92,881,392
Ensembl chr 7:92,605,728...92,882,068
JBrowse link
G Ezr ezrin multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EZR mRNA
panobinostat results in increased expression of EZR mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:47,287,872...47,331,412
Ensembl chr 1:47,287,874...47,331,412
JBrowse link
G F2rl1 F2R like trypsin receptor 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA
panobinostat results in increased expression of F2RL1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:25,222,324...25,235,275
Ensembl chr 2:25,222,328...25,235,275
JBrowse link
G F2rl2 coagulation factor II (thrombin) receptor-like 2 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F2RL2 mRNA
panobinostat results in decreased expression of F2RL2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:26,240,385...26,245,533
Ensembl chr 2:26,240,385...26,245,533
JBrowse link
G Fabp3 fatty acid binding protein 3 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA
panobinostat results in increased expression of FABP3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:148,528,854...148,535,597
Ensembl chr 5:148,528,725...148,535,565
JBrowse link
G Fam110b family with sequence similarity 110, member B multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM110B mRNA CTD PMID:27188386 NCBI chr 5:18,762,488...18,903,818
Ensembl chr 5:18,901,039...18,902,672
JBrowse link
G Fam124a family with sequence similarity 124 member A decreases expression
multiple interactions
ISO panobinostat results in decreased expression of FAM124A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM124A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:45,711,994...45,780,395
Ensembl chr15:45,712,821...45,780,405
JBrowse link
G Fam13c family with sequence similarity 13, member C multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM13C mRNA
panobinostat results in increased expression of FAM13C mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr20:19,358,869...19,470,212
Ensembl chr20:19,360,230...19,479,325
JBrowse link
G Fam149a family with sequence similarity 149, member A decreases expression
multiple interactions
ISO panobinostat results in decreased expression of FAM149A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM149A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr16:50,049,816...50,105,962
Ensembl chr16:50,049,828...50,107,856
JBrowse link
G Fam155a family with sequence similarity 155, member A multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM155A mRNA
panobinostat results in decreased expression of FAM155A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr16:85,528,126...86,053,447 JBrowse link
G Fam163a family with sequence similarity 163, member A affects expression
multiple interactions
ISO panobinostat affects the expression of FAM163A mRNA
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FAM163A mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FAM163A mRNA]
CTD PMID:26733615 NCBI chr13:73,741,674...73,820,114
Ensembl chr13:73,741,679...73,819,896
JBrowse link
G Fam168a family with sequence similarity 168, member A decreases expression
multiple interactions
ISO panobinostat results in decreased expression of FAM168A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM168A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:165,723,278...165,880,612
Ensembl chr 1:165,724,451...165,878,652
JBrowse link
G Fam241a family with sequence similarity 241 member A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM241A mRNA CTD PMID:27188386 NCBI chr 2:232,214,331...232,245,319
Ensembl chr 2:232,214,331...232,245,319
JBrowse link
G Fam43a family with sequence similarity 43, member A increases expression
multiple interactions
ISO panobinostat results in increased expression of FAM43A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:73,676,601...73,679,003
Ensembl chr11:73,676,601...73,678,984
JBrowse link
G Fam71f1 family with sequence similarity 71, member F1 decreases expression ISO panobinostat results in decreased expression of FAM71F1 mRNA CTD PMID:26272509 NCBI chr 4:56,591,719...56,615,157
Ensembl chr 4:56,591,715...56,615,158
JBrowse link
G Fam89a family with sequence similarity 89, member A increases expression
multiple interactions
ISO panobinostat results in increased expression of FAM89A mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM89A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:57,502,308...57,514,896
Ensembl chr19:57,502,308...57,514,896
JBrowse link
G Fank1 fibronectin type III and ankyrin repeat domains 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FANK1 mRNA
panobinostat results in decreased expression of FANK1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:205,842,469...205,954,152
Ensembl chr 1:205,842,489...205,950,371
JBrowse link
G Fat3 FAT atypical cadherin 3 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of FAT3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAT3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:14,417,039...15,011,596
Ensembl chr 8:14,417,584...14,880,644
JBrowse link
G Faxc failed axon connections homolog, metaxin like GST domain containing affects expression
multiple interactions
ISO panobinostat affects the expression of FAXC mRNA
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FAXC mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FAXC mRNA]
CTD PMID:26733615 NCBI chr 5:36,076,565...36,135,884
Ensembl chr 5:36,076,565...36,135,884
JBrowse link
G Fbln7 fibulin 7 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of FBLN7 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:121,407,981...121,441,660
Ensembl chr 3:121,408,146...121,440,787
JBrowse link
G Fbn1 fibrillin 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBN1 mRNA
panobinostat results in decreased expression of FBN1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:117,569,708...117,766,160
Ensembl chr 3:117,569,697...117,766,120
JBrowse link
G Fbxl13 F-box and leucine-rich repeat protein 13 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXL13 mRNA CTD PMID:27188386 NCBI chr 4:10,020,349...10,170,012
Ensembl chr 4:10,020,349...10,167,023
JBrowse link
G Fbxo2 F-box protein 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of FBXO2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXO2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:164,972,483...164,977,912
Ensembl chr 5:164,972,480...164,977,916
JBrowse link
G Fbxo8 F-box protein 8 multiple interactions
affects expression
ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FBXO8 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FBXO8 mRNA] CTD PMID:26733615 NCBI chr16:37,131,566...37,177,033
Ensembl chr16:37,131,345...37,177,033
JBrowse link
G Fbxo9 f-box protein 9 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO9 mRNA CTD PMID:27188386 NCBI chr 8:85,388,331...85,413,896
Ensembl chr 8:85,388,333...85,413,484
JBrowse link
G Fermt1 fermitin family member 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of FERMT1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FERMT1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:125,566,744...125,607,864
Ensembl chr 3:125,566,643...125,607,735
JBrowse link
G Fez1 fasciculation and elongation protein zeta 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZ1 mRNA
panobinostat results in decreased expression of FEZ1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:39,305,128...39,350,270
Ensembl chr 8:39,305,128...39,350,270
JBrowse link
G Fezf2 Fez family zinc finger 2 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FEZF2 mRNA
panobinostat results in decreased expression of FEZF2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:12,825,333...12,831,496
Ensembl chr15:12,827,707...12,831,496
JBrowse link
G Fgd5 FYVE, RhoGEF and PH domain containing 5 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGD5 mRNA
panobinostat results in increased expression of FGD5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:123,865,557...123,962,904
Ensembl chr 4:123,865,725...123,962,881
JBrowse link
G Fgf18 fibroblast growth factor 18 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF18 mRNA CTD PMID:27188386 NCBI chr10:18,047,109...18,082,290
Ensembl chr10:18,047,109...18,063,391
JBrowse link
G Fgf19 fibroblast growth factor 19 increases expression
multiple interactions
ISO panobinostat results in increased expression of FGF19 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF19 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:218,058,405...218,061,693
Ensembl chr 1:218,058,405...218,061,693
JBrowse link
G Fgf8 fibroblast growth factor 8 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of FGF8 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF8 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:265,492,949...265,498,965
Ensembl chr 1:265,493,124...265,498,831
JBrowse link
G Fgf9 fibroblast growth factor 9 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of FGF9 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:38,341,657...38,386,945
Ensembl chr15:38,341,089...38,387,316
JBrowse link
G Fgfbp3 fibroblast growth factor binding protein 3 increases expression
multiple interactions
ISO panobinostat results in increased expression of FGFBP3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFBP3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:255,555,050...255,557,055
Ensembl chr 1:255,555,050...255,557,055
JBrowse link
G Fgfr3 fibroblast growth factor receptor 3 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGFR3 mRNA
panobinostat results in increased expression of FGFR3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:82,272,322...82,287,739
Ensembl chr14:82,273,070...82,287,706
JBrowse link
G Fhod3 formin homology 2 domain containing 3 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FHOD3 mRNA
panobinostat results in decreased expression of FHOD3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:16,650,786...17,332,209
Ensembl chr18:16,650,806...17,332,210
JBrowse link
G Fign fidgetin, microtubule severing factor affects expression
multiple interactions
ISO panobinostat affects the expression of FIGN mRNA
(+)-JQ1 compound promotes the reaction [panobinostat affects the expression of FIGN mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of FIGN mRNA]
CTD PMID:26733615 NCBI chr 3:49,992,250...50,120,601
Ensembl chr 3:49,992,397...50,120,392
JBrowse link
G Fjx1 four-jointed box kinase 1 decreases expression ISO panobinostat results in decreased expression of FJX1 mRNA CTD PMID:26272509 NCBI chr 3:92,288,818...92,290,919
Ensembl chr 3:92,288,818...92,290,919
JBrowse link
G Flnb filamin B increases expression ISO panobinostat results in increased expression of FLNB mRNA CTD PMID:26272509 NCBI chr15:18,750,152...18,883,019
Ensembl chr15:18,750,118...18,883,005
JBrowse link
G Flrt2 fibronectin leucine rich transmembrane protein 2 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FLRT2 mRNA
panobinostat results in decreased expression of FLRT2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:119,518,459...119,613,534
Ensembl chr 6:119,519,714...119,609,296
JBrowse link
G Flt1 Fms related receptor tyrosine kinase 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA
panobinostat results in increased expression of FLT1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr12:9,033,993...9,205,886
Ensembl chr12:9,034,308...9,205,905
JBrowse link
G Fndc5 fibronectin type III domain containing 5 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FNDC5 mRNA
panobinostat results in decreased expression of FNDC5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:147,323,240...147,330,266
Ensembl chr 5:147,323,240...147,330,266
JBrowse link
G Foxc1 forkhead box C1 increases expression
multiple interactions
ISO panobinostat results in increased expression of FOXC1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:33,947,501...33,951,484
Ensembl chr17:33,947,506...33,951,484
JBrowse link
G Foxc2 forkhead box C2 increases expression
multiple interactions
ISO panobinostat results in increased expression of FOXC2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXC2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:53,044,379...53,047,081
Ensembl chr19:53,044,379...53,047,081
JBrowse link
G Foxd3 forkhead box D3 increases expression
multiple interactions
ISO panobinostat results in increased expression of FOXD3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:118,346,283...118,349,120 JBrowse link
G Foxh1 forkhead box H1 increases expression
multiple interactions
ISO panobinostat results in increased expression of FOXH1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:117,730,307...117,733,076
Ensembl chr 7:117,730,307...117,732,387
JBrowse link
G Foxo1 forkhead box O1 increases expression
multiple interactions
ISO panobinostat results in increased expression of FOXO1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
JBrowse link
G Fras1 Fraser extracellular matrix complex subunit 1 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of FRAS1 mRNA CTD PMID:21791302 NCBI chr14:14,438,392...14,853,016
Ensembl chr14:14,439,082...14,689,554
JBrowse link
G Frem1 Fras1 related extracellular matrix 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FREM1 mRNA
panobinostat results in increased expression of FREM1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:101,018,009...101,166,794
Ensembl chr 5:101,020,448...101,166,651
JBrowse link
G Frrs1l ferric-chelate reductase 1-like multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA
panobinostat results in decreased expression of FRRS1L mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:73,997,958...74,029,381
Ensembl chr 5:74,000,227...74,029,238
JBrowse link
G Frzb frizzled-related protein multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRZB mRNA
panobinostat results in decreased expression of FRZB mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:67,635,604...67,668,772
Ensembl chr 3:67,635,607...67,668,772
JBrowse link
G Fut4 fucosyltransferase 4 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FUT4 mRNA
panobinostat results in increased expression of FUT4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:13,258,768...13,262,729
Ensembl chr 8:13,258,768...13,262,729
JBrowse link
G Fut9 fucosyltransferase 9 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FUT9 mRNA
panobinostat results in decreased expression of FUT9 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:40,032,855...40,237,591
Ensembl chr 5:40,032,855...40,237,591
JBrowse link
G Fzd10 frizzled class receptor 10 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD10 mRNA
panobinostat results in increased expression of FZD10 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr12:31,757,407...31,760,604
Ensembl chr12:31,757,407...31,760,604
JBrowse link
G Fzd2 frizzled class receptor 2 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD2 mRNA
panobinostat results in decreased expression of FZD2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:90,550,147...90,552,057
Ensembl chr10:90,550,147...90,552,057
JBrowse link
G Fzd3 frizzled class receptor 3 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD3 mRNA
panobinostat results in decreased expression of FZD3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:48,601,259...48,670,257
Ensembl chr15:48,601,266...48,670,257
JBrowse link
G Fzd5 frizzled class receptor 5 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD5 mRNA
panobinostat results in decreased expression of FZD5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:71,443,784...71,445,541
Ensembl chr 9:71,443,588...71,445,739
JBrowse link
G Fzd7 frizzled class receptor 7 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA
panobinostat results in increased expression of FZD7 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:66,305,731...66,308,550
Ensembl chr 9:66,305,731...66,308,550
JBrowse link
G Fzd8 frizzled class receptor 8 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FZD8 mRNA CTD PMID:27188386 NCBI chr17:62,259,910...62,267,239
Ensembl chr17:62,262,129...62,265,113
JBrowse link
G Gabrb2 gamma-aminobutyric acid type A receptor subunit beta 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB2 mRNA
panobinostat results in increased expression of GABRB2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:27,973,694...28,193,072
Ensembl chr10:27,973,681...28,187,565
JBrowse link
G Gabrb3 gamma-aminobutyric acid type A receptor subunit beta 3 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA
panobinostat results in increased expression of GABRB3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:113,034,251...113,265,364
Ensembl chr 1:112,976,770...113,265,364
JBrowse link
G Gabrp gamma-aminobutyric acid type A receptor subunit pi multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRP mRNA CTD PMID:27188386 NCBI chr10:18,484,257...18,510,604
Ensembl chr10:18,485,514...18,506,337
JBrowse link
G Gad1 glutamate decarboxylase 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA
panobinostat results in increased expression of GAD1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:56,861,440...56,902,139
Ensembl chr 3:56,861,396...56,902,157
JBrowse link
G Gad2 glutamate decarboxylase 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GAD2 mRNA CTD PMID:27188386 NCBI chr17:89,171,576...89,234,770
Ensembl chr17:89,171,250...89,238,040
JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45A mRNA; Panobinostat promotes the reaction [SRT2183 results in increased expression of GADD45A mRNA]; SRT2183 promotes the reaction [Panobinostat results in increased expression of GADD45A mRNA]
panobinostat results in increased expression of GADD45A mRNA
CTD PMID:23681230, PMID:26272509, PMID:27188386 NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta increases expression
multiple interactions
ISO panobinostat results in increased expression of GADD45B mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GADD45B mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:11,646,283...11,648,338
Ensembl chr 7:11,646,269...11,648,322
JBrowse link
G Gadd45g growth arrest and DNA-damage-inducible, gamma multiple interactions
increases expression
ISO GADD45G protein affects the susceptibility to [SRT2183 co-treated with panobinostat]; panobinostat inhibits the reaction [STAT3 protein binds to GADD45G promoter]; panobinostat promotes the reaction [resveratrol inhibits the reaction [STAT3 protein binds to GADD45G promoter]]; panobinostat promotes the reaction [resveratrol results in increased expression of GADD45G mRNA]; panobinostat promotes the reaction [SRT2183 inhibits the reaction [STAT3 protein binds to GADD45G promoter]]; panobinostat promotes the reaction [SRT2183 results in increased expression of GADD45G mRNA]; resveratrol promotes the reaction [panobinostat results in increased expression of GADD45G mRNA]; SRT2183 promotes the reaction [panobinostat results in increased expression of GADD45G mRNA] CTD PMID:23681230 NCBI chr17:13,391,474...13,393,219
Ensembl chr17:13,391,467...13,393,243
JBrowse link
G Galnt18 polypeptide N-acetylgalactosaminyltransferase 18 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT18 mRNA
panobinostat results in increased expression of GALNT18 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:176,296,186...176,607,466
Ensembl chr 1:176,296,193...176,607,466
JBrowse link
G Galnt3 polypeptide N-acetylgalactosaminyltransferase 3 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA
panobinostat results in increased expression of GALNT3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:52,174,469...52,212,395
Ensembl chr 3:52,175,547...52,212,412
JBrowse link
G Gap43 growth associated protein 43 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA
panobinostat results in increased expression of GAP43 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:58,624,198...58,717,916
Ensembl chr11:58,624,198...58,717,914
JBrowse link
G Gas7 growth arrest specific 7 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAS7 mRNA
panobinostat results in increased expression of GAS7 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:54,010,723...54,240,805
Ensembl chr10:54,126,486...54,236,476
JBrowse link
G Gata2 GATA binding protein 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA2 mRNA
panobinostat results in increased expression of GATA2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:120,129,028...120,142,490
Ensembl chr 4:120,133,713...120,142,488
JBrowse link
G Gata3 GATA binding protein 3 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA
panobinostat results in increased expression of GATA3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:72,419,752...72,452,043
Ensembl chr17:72,429,618...72,450,681
JBrowse link
G Gata4 GATA binding protein 4 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GATA4 mRNA
panobinostat results in decreased expression of GATA4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:46,386,703...46,458,679
Ensembl chr15:46,386,712...46,432,965
JBrowse link
G Gata6 GATA binding protein 6 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA6 mRNA CTD PMID:27188386 NCBI chr18:2,415,821...2,447,087
Ensembl chr18:2,416,552...2,446,338
JBrowse link
G Gbx2 gastrulation brain homeobox 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of GBX2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GBX2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:97,063,265...97,065,855
Ensembl chr 9:97,063,728...97,065,817
JBrowse link
G Gchfr GTP cyclohydrolase I feedback regulator increases expression
multiple interactions
ISO panobinostat results in increased expression of GCHFR mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GCHFR mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:110,975,923...110,979,957
Ensembl chr 3:110,975,923...110,979,957
JBrowse link
G Gdf10 growth differentiation factor 10 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDF10 mRNA CTD PMID:27188386 NCBI chr16:10,250,508...10,262,383
Ensembl chr16:10,250,404...10,263,150
JBrowse link
G Gja3 gap junction protein, alpha 3 increases expression
multiple interactions
ISO panobinostat results in increased expression of GJA3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJA3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:37,298,607...37,325,370
Ensembl chr15:37,299,738...37,325,178
JBrowse link
G Gjb2 gap junction protein, beta 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GJB2 mRNA CTD PMID:27188386 NCBI chr15:37,377,313...37,394,494
Ensembl chr15:37,377,316...37,383,277
JBrowse link
G Gje1 gap junction protein, epsilon 1 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of GJE1 mRNA CTD PMID:21791302 NCBI chr 1:8,883,767...8,887,721
Ensembl chr 1:8,883,961...8,885,967
JBrowse link
G Gkap1 G kinase anchoring protein 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GKAP1 mRNA
panobinostat results in decreased expression of GKAP1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:6,785,428...6,825,145
Ensembl chr17:6,785,428...6,825,144
JBrowse link
G Glb1l galactosidase, beta 1-like multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of GLB1L mRNA CTD PMID:21791302 NCBI chr 9:82,400,457...82,410,970
Ensembl chr 9:82,400,569...82,410,904
JBrowse link
G Glcci1 glucocorticoid induced 1 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of GLCCI1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLCCI1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:34,282,625...34,612,709
Ensembl chr 4:34,282,625...34,614,438
JBrowse link
G Glis3 GLIS family zinc finger 3 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of GLIS3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GLIS3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:246,380,816...246,564,385
Ensembl chr 1:246,380,889...246,785,360
JBrowse link
G Glrx2 glutaredoxin 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLRX2 mRNA
panobinostat results in increased expression of GLRX2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:60,529,057...60,552,115
Ensembl chr13:60,529,932...60,537,916
JBrowse link
G Gls glutaminase multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLS mRNA
panobinostat results in increased expression of GLS mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:54,212,622...54,284,879
Ensembl chr 9:54,212,767...54,284,872
JBrowse link
G Gnas GNAS complex locus multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNAS mRNA
panobinostat results in increased expression of GNAS mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:172,374,957...172,434,988
Ensembl chr 3:172,374,957...172,428,483
Ensembl chr 3:172,374,957...172,428,483
JBrowse link
G Gng11 G protein subunit gamma 11 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GNG11 mRNA
panobinostat results in increased expression of GNG11 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:28,989,170...28,994,610
Ensembl chr 4:28,989,115...28,993,621
JBrowse link
G Gng8 G protein subunit gamma 8 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GNG8 mRNA
panobinostat results in decreased expression of GNG8 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:78,818,360...78,822,224
Ensembl chr 1:78,818,404...78,822,224
JBrowse link
G Gnl3l G protein nucleolar 3 like multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of GNL3L mRNA CTD PMID:21791302 NCBI chr  X:20,037,558...20,070,505
Ensembl chr  X:20,034,882...20,070,578
JBrowse link
G Gpc3 glypican 3 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of GPC3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:139,579,268...139,947,093
Ensembl chr  X:139,579,268...139,916,883
JBrowse link
G Gpc4 glypican 4 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of GPC4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:139,354,325...139,464,876
Ensembl chr  X:139,354,155...139,464,798
JBrowse link
G Gpc6 glypican 6 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA
panobinostat results in decreased expression of GPC6 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:102,164,091...103,174,721
Ensembl chr15:102,164,751...103,170,847
JBrowse link
G Gpd1l glycerol-3-phosphate dehydrogenase 1-like increases expression
multiple interactions
ISO panobinostat results in increased expression of GPD1L mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPD1L mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:122,957,570...122,987,236
Ensembl chr 8:122,954,948...122,987,191
JBrowse link
G Gpr173 G-protein coupled receptor 173 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of GPR173 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR173 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:22,417,753...22,418,873
Ensembl chr  X:22,417,753...22,418,873
JBrowse link
G Gpr27 G protein-coupled receptor 27 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of GPR27 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPR27 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:132,137,793...132,138,926
Ensembl chr 4:132,137,793...132,138,926
JBrowse link
G Gpr37 G protein-coupled receptor 37 increases expression
multiple interactions
ISO panobinostat results in increased expression of GPR37 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GPR37 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:51,822,163...51,844,228
Ensembl chr 4:51,822,153...51,844,331
JBrowse link
G Grem1 gremlin 1, DAN family BMP antagonist increases expression
multiple interactions
ISO panobinostat results in increased expression of GREM1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:105,203,309...105,214,989
Ensembl chr 3:105,203,309...105,214,989
JBrowse link
G Grhl1 grainyhead-like transcription factor 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL1 mRNA CTD PMID:27188386 NCBI chr 6:43,734,837...43,795,757
Ensembl chr 6:43,743,702...43,794,342
JBrowse link
G Grhl2 grainyhead-like transcription factor 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL2 mRNA CTD PMID:27188386 NCBI chr 7:76,058,623...76,197,360
Ensembl chr 7:76,059,386...76,197,856
JBrowse link
G Grhl3 grainyhead-like transcription factor 3 increases expression
multiple interactions
ISO panobinostat results in increased expression of GRHL3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:153,893,039...153,925,045
Ensembl chr 5:153,893,039...153,924,896
JBrowse link
G Gria1 glutamate ionotropic receptor AMPA type subunit 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA1 mRNA CTD PMID:27188386 NCBI chr10:42,441,723...42,760,200
Ensembl chr10:42,614,713...42,760,200
JBrowse link
G Gria3 glutamate ionotropic receptor AMPA type subunit 3 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of GRIA3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIA3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:127,561,843...127,829,763
Ensembl chr  X:127,562,660...127,829,753
JBrowse link
G Grik3 glutamate ionotropic receptor kainate type subunit 3 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of GRIK3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIK3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:143,500,441...143,715,546
Ensembl chr 5:143,500,441...143,715,546
JBrowse link
G Grin2a glutamate ionotropic receptor NMDA type subunit 2A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRIN2A mRNA CTD PMID:27188386 NCBI chr10:5,707,806...6,123,568
Ensembl chr10:5,930,298...6,119,990
JBrowse link
G Grm3 glutamate metabotropic receptor 3 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GRM3 mRNA
panobinostat results in decreased expression of GRM3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:21,316,761...21,567,561
Ensembl chr 4:21,317,695...21,560,490
JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of GSTA1 mRNA CTD PMID:21791302 NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
JBrowse link
G Gsta2 glutathione S-transferase alpha 2 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of GSTA2 mRNA CTD PMID:21791302 NCBI chr 8:85,640,081...85,645,621 JBrowse link
G Gsta5 glutathione S-transferase alpha 5 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of GSTA5 mRNA CTD PMID:21791302 NCBI chr 8:85,553,659...85,564,914
Ensembl chr 8:85,553,734...85,565,179
JBrowse link
G Gucy1a1 guanylate cyclase 1 soluble subunit alpha 1 multiple interactions
affects expression
ISO (+)-JQ1 compound promotes the reaction [panobinostat affects the expression of GUCY1A1 mRNA]; panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of GUCY1A1 mRNA] CTD PMID:26733615 NCBI chr 2:181,045,694...181,103,321
Ensembl chr 2:181,045,703...181,102,918
JBrowse link
G Gypc glycophorin C (Gerbich blood group) increases expression
multiple interactions
ISO panobinostat results in increased expression of GYPC mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GYPC mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:25,312,386...25,344,614
Ensembl chr18:25,312,387...25,344,614
JBrowse link
G H2ax H2A.X variant histone multiple interactions
increases expression
ISO manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Resveratrol promotes the reaction [Panobinostat results in increased expression of H2AX protein]]; Panobinostat promotes the reaction [SRT2183 results in increased expression of H2AX protein modified form]; Resveratrol promotes the reaction [Panobinostat results in increased expression of H2AX protein] CTD PMID:22923501, PMID:23681230 NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
JBrowse link
G H2bc12 H2B clustered histone 12 decreases expression
multiple interactions
ISO Panobinostat results in decreased expression of H2BC12 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:44,527,421...44,527,801
Ensembl chr17:44,527,421...44,527,801
JBrowse link
G H3f4 H3.4 histone increases acetylation ISO Panobinostat results in increased acetylation of H3-4 protein CTD PMID:19215824 NCBI chr10:45,304,696...45,305,106 JBrowse link
G Hacd1 3-hydroxyacyl-CoA dehydratase 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of HACD1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HACD1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:81,173,238...81,196,012
Ensembl chr17:81,173,713...81,187,739
JBrowse link
G Hand1 heart and neural crest derivatives expressed 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAND1 mRNA CTD PMID:27188386 NCBI chr10:43,250,729...43,253,296
Ensembl chr10:43,250,745...43,253,296
JBrowse link
G Hapln1 hyaluronan and proteoglycan link protein 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA
panobinostat results in increased expression of HAPLN1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:18,354,542...18,419,077
Ensembl chr 2:18,354,542...18,419,071
JBrowse link
G Has2 hyaluronan synthase 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAS2 mRNA
panobinostat results in increased expression of HAS2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:96,438,046...96,464,049
Ensembl chr 7:96,438,046...96,464,049
JBrowse link
G Hck HCK proto-oncogene, Src family tyrosine kinase multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HCK mRNA CTD PMID:27188386 NCBI chr 3:148,579,917...148,623,026
Ensembl chr 3:148,579,920...148,623,033
JBrowse link
G Hdac8 histone deacetylase 8 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HDAC8 mRNA
panobinostat results in increased expression of HDAC8 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:72,163,777...72,370,058
Ensembl chr  X:72,163,777...72,370,044
JBrowse link
G Hdac9 histone deacetylase 9 decreases expression ISO Panobinostat results in decreased expression of HDAC9 mRNA CTD PMID:30481203 NCBI chr 6:53,487,367...54,358,694
Ensembl chr 6:53,488,883...54,059,119
JBrowse link
G Heg1 heart development protein with EGF-like domains 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA
panobinostat results in decreased expression of HEG1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:70,234,248...70,322,966
Ensembl chr11:70,236,888...70,322,690
JBrowse link
G Hes2 hes family bHLH transcription factor 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of HES2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HES2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:169,338,097...169,339,142
Ensembl chr 5:169,338,097...169,339,142
JBrowse link
G Hes5 hes family bHLH transcription factor 5 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of HES5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:172,364,421...172,365,188
Ensembl chr 5:172,364,421...172,365,188
JBrowse link
G Hesx1 HESX homeobox 1 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of HESX1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr16:2,616,538...2,636,708
Ensembl chr16:2,634,603...2,636,708
JBrowse link
G Hey2 hes-related family bHLH transcription factor with YRPW motif 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA
panobinostat results in increased expression of HEY2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:29,191,170...29,201,257
Ensembl chr 1:29,191,192...29,201,531
JBrowse link
G Hhip Hedgehog-interacting protein multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHIP mRNA CTD PMID:27188386 NCBI chr19:31,525,134...31,614,487
Ensembl chr19:31,524,671...31,614,246
JBrowse link
G Hk1 hexokinase 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of HK1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HK1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr20:31,911,460...31,979,780
Ensembl chr20:31,912,262...31,956,649
JBrowse link
G Hmgcll1 3-hydroxymethyl-3-methylglutaryl-CoA lyase-like 1 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of HMGCLL1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HMGCLL1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:83,069,837...83,204,778
Ensembl chr 8:83,070,545...83,205,441
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMOX1 mRNA
panobinostat results in increased expression of HMOX1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Hmx2 H6 family homeobox 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA CTD PMID:27188386 NCBI chr 1:203,515,605...203,523,266
Ensembl chr 1:203,515,609...203,523,358
JBrowse link
G Hnmt histamine N-methyltransferase increases expression
multiple interactions
ISO panobinostat results in increased expression of HNMT mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HNMT mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:905,111...937,038
Ensembl chr 3:904,765...937,102
JBrowse link
G Hnrnpr heterogeneous nuclear ribonucleoprotein R multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HNRNPR mRNA CTD PMID:27188386 NCBI chr 5:154,668,194...154,699,967
Ensembl chr 5:154,668,179...154,699,966
JBrowse link
G Homez homeobox and leucine zipper encoding multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HOMEZ mRNA CTD PMID:27188386 NCBI chr15:33,510,454...33,528,018
Ensembl chr15:33,510,458...33,527,031
JBrowse link
G Hoxa1 homeobox A1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HOXA1 mRNA CTD PMID:27188386 NCBI chr 4:82,124,358...82,127,182
Ensembl chr 4:82,125,406...82,127,066
JBrowse link
G Hpdl 4-hydroxyphenylpyruvate dioxygenase-like multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA
panobinostat results in increased expression of HPDL mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:135,675,826...135,677,432
Ensembl chr 5:135,675,832...135,677,432
JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPGD mRNA CTD PMID:27188386 NCBI chr16:37,457,134...37,495,758
Ensembl chr16:37,457,135...37,495,758
JBrowse link
G Hps1 HPS1, biogenesis of lysosomal organelles complex 3 subunit 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPS1 mRNA
panobinostat results in increased expression of HPS1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:261,989,178...262,015,282
Ensembl chr 1:261,989,178...262,015,153
JBrowse link
G Hrk harakiri, BCL2 interacting protein increases expression
multiple interactions
ISO panobinostat results in increased expression of HRK mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HRK mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr12:44,008,879...44,029,211 JBrowse link
G Hs3st3b1 heparan sulfate-glucosamine 3-sulfotransferase 3B1 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of HS3ST3B1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HS3ST3B1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:50,369,097...50,402,584
Ensembl chr10:50,366,952...50,402,616
JBrowse link
G Hspa4l heat shock protein family A (Hsp70) member 4 like increases expression
multiple interactions
ISO panobinostat results in increased expression of HSPA4L mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HSPA4L mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:127,625,737...127,682,864
Ensembl chr 2:127,625,683...127,677,503
JBrowse link
G Hspb11 heat shock protein family B (small), member 11 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HSPB11 mRNA
panobinostat results in decreased expression of HSPB11 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:126,856,128...126,882,913
Ensembl chr 5:126,856,705...126,882,909
JBrowse link
G Icam1 intercellular adhesion molecule 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of ICAM1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ICAM1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
JBrowse link
G Id4 inhibitor of DNA binding 4, HLH protein multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID4 mRNA
panobinostat results in increased expression of ID4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:16,692,557...16,695,126
Ensembl chr17:16,692,557...16,695,126
JBrowse link
G Idh3a isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA
panobinostat results in increased expression of IDH3A mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:59,164,601...59,183,899
Ensembl chr 8:59,164,572...59,183,908
JBrowse link
G Ier3 immediate early response 3 increases expression
multiple interactions
ISO panobinostat results in increased expression of IER3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IER3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr20:3,438,798...3,440,002
Ensembl chr20:3,438,798...3,440,769
JBrowse link
G Ifi30 IFI30, lysosomal thiol reductase multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI30 mRNA
panobinostat results in increased expression of IFI30 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr16:20,426,566...20,430,772
Ensembl chr16:20,426,566...20,430,752
JBrowse link
G Ifnar2 interferon alpha and beta receptor subunit 2 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of IFNAR2 mRNA CTD PMID:21791302 NCBI chr11:31,527,790...31,559,834
Ensembl chr11:31,539,016...31,558,851
JBrowse link
G Igdcc3 immunoglobulin superfamily, DCC subclass, member 3 increases expression
multiple interactions
ISO panobinostat results in increased expression of IGDCC3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGDCC3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:70,630,546...70,685,882
Ensembl chr 8:70,630,767...70,684,115
JBrowse link
G Igf2 insulin-like growth factor 2 increases expression ISO panobinostat results in increased expression of IGF2 mRNA CTD PMID:26272509 NCBI chr 1:215,828,102...215,839,081
Ensembl chr 1:215,828,102...215,846,911
JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 decreases expression ISO panobinostat results in decreased expression of IGFBP3 mRNA CTD PMID:26272509 NCBI chr14:87,457,647...87,465,374
Ensembl chr14:87,457,647...87,465,374
JBrowse link
G Igfbp7 insulin-like growth factor binding protein 7 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IGFBP7 mRNA
panobinostat results in increased expression of IGFBP7 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:33,010,300...33,070,193
Ensembl chr14:33,010,300...33,070,190
JBrowse link
G Igsf21 immunoglobin superfamily, member 21 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IGSF21 mRNA CTD PMID:27188386 NCBI chr 5:158,503,090...158,735,702
Ensembl chr 5:158,503,244...158,549,496
JBrowse link
G Il17rd interleukin 17 receptor D decreases expression
multiple interactions
ISO panobinostat results in decreased expression of IL17RD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr16:2,670,471...2,737,271
Ensembl chr16:2,670,618...2,731,808
JBrowse link
G Il1rapl1 interleukin 1 receptor accessory protein-like 1 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of IL1RAPL1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL1RAPL1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:55,439,388...57,004,865
Ensembl chr  X:55,439,578...56,765,893
JBrowse link
G Il20rb interleukin 20 receptor subunit beta increases expression
multiple interactions
ISO panobinostat results in increased expression of IL20RB mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:108,745,906...108,778,561
Ensembl chr 8:108,747,204...108,777,717
JBrowse link
G Il27ra interleukin 27 receptor subunit alpha increases expression
multiple interactions
ISO panobinostat results in increased expression of IL27RA mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL27RA mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:25,151,835...25,163,995
Ensembl chr19:25,149,897...25,164,086
JBrowse link
G Il3ra interleukin 3 receptor subunit alpha multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of IL3RA mRNA CTD PMID:21791302 NCBI chr12:18,534,762...18,542,508
Ensembl chr12:18,534,767...18,540,166
JBrowse link
G Inf2 inverted formin 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INF2 mRNA
panobinostat results in increased expression of INF2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:137,162,593...137,180,198
Ensembl chr 6:137,164,535...137,177,622
JBrowse link
G Inhbe inhibin subunit beta E multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBE mRNA
panobinostat results in increased expression of INHBE mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:70,641,423...70,642,848
Ensembl chr 7:70,640,075...70,643,169
JBrowse link
G Inpp4b inositol polyphosphate-4-phosphatase type II B multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP4B mRNA CTD PMID:27188386 NCBI chr19:29,592,889...30,341,528
Ensembl chr19:29,597,905...29,968,424
JBrowse link
G Inpp5d inositol polyphosphate-5-phosphatase D multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INPP5D mRNA CTD PMID:27188386 NCBI chr 9:94,745,220...94,850,778
Ensembl chr 9:94,745,217...94,850,771
JBrowse link
G Insc INSC, spindle orientation adaptor protein increases expression
multiple interactions
ISO panobinostat results in increased expression of INSC mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INSC mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:184,299,200...184,407,487
Ensembl chr 1:184,299,250...184,407,480
JBrowse link
G Iqca1 IQ motif containing with AAA domain 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQCA1 mRNA
panobinostat results in increased expression of IQCA1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:97,190,240...97,298,760 JBrowse link
G Iqgap1 IQ motif containing GTPase activating protein 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IQGAP1 mRNA
panobinostat results in increased expression of IQGAP1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:142,525,041...142,615,673
Ensembl chr 1:142,525,046...142,615,673
JBrowse link
G Irf6 interferon regulatory factor 6 increases expression
multiple interactions
ISO panobinostat results in increased expression of IRF6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRF6 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:111,870,121...111,889,328
Ensembl chr13:111,870,121...111,889,328
JBrowse link
G Irx1 iroquois homeobox 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA
panobinostat results in increased expression of IRX1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:33,910,912...33,916,741
Ensembl chr 1:33,910,912...33,916,741
JBrowse link
G Irx2 iroquois homeobox 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA
panobinostat results in increased expression of IRX2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:33,270,388...33,275,868
Ensembl chr 1:33,271,977...33,275,540
JBrowse link
G Irx3 iroquois homeobox 3 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX3 mRNA
panobinostat results in increased expression of IRX3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:15,838,714...15,842,135
Ensembl chr19:15,838,714...15,840,990
JBrowse link
G Isl1 ISL LIM homeobox 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ISL1 mRNA CTD PMID:27188386 NCBI chr 2:48,488,911...48,501,217
Ensembl chr 2:48,487,736...48,501,436
JBrowse link
G Itga8 integrin subunit alpha 8 increases expression
multiple interactions
ISO panobinostat results in increased expression of ITGA8 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA8 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:79,321,893...79,676,927
Ensembl chr17:79,321,900...79,676,499
JBrowse link
G Itga9 integrin subunit alpha 9 increases expression
multiple interactions
ISO panobinostat results in increased expression of ITGA9 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITGA9 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:127,271,029...127,576,709
Ensembl chr 8:127,271,289...127,572,988
JBrowse link
G Itgb5 integrin subunit beta 5 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of ITGB5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ITGB5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:70,056,500...70,172,164
Ensembl chr11:70,056,500...70,172,372
JBrowse link
G Itm2a integral membrane protein 2A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITM2A mRNA CTD PMID:27188386 NCBI chr  X:78,490,872...78,496,814
Ensembl chr  X:78,490,866...78,496,847
JBrowse link
G Itpr2 inositol 1,4,5-trisphosphate receptor, type 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITPR2 mRNA
panobinostat results in increased expression of ITPR2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:180,423,452...180,800,088
Ensembl chr 4:180,538,389...180,722,358
JBrowse link
G Jade2 jade family PHD finger 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of JADE2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JADE2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:37,269,132...37,315,638
Ensembl chr10:37,270,183...37,311,625
JBrowse link
G Jazf1 JAZF zinc finger 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of JAZF1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:82,834,181...83,141,430
Ensembl chr 4:82,836,260...83,137,527
JBrowse link
G Jcad junctional cadherin 5 associated increases expression
multiple interactions
ISO panobinostat results in increased expression of JCAD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JCAD mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:55,667,754...55,709,738
Ensembl chr17:55,670,331...55,709,740
JBrowse link
G Jdp2 Jun dimerization protein 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of JDP2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JDP2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:109,464,910...109,505,591
Ensembl chr 6:109,466,060...109,505,161
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases expression ISO panobinostat results in increased expression of JUN mRNA CTD PMID:26272509 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Kank4 KN motif and ankyrin repeat domains 4 increases expression
multiple interactions
ISO panobinostat results in increased expression of KANK4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KANK4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:117,376,425...117,440,643
Ensembl chr 5:117,376,423...117,440,254
JBrowse link
G Kat2b lysine acetyltransferase 2B multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA
panobinostat results in decreased expression of KAT2B mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:4,440,982...4,492,949 JBrowse link
G Kat6a lysine acetyltransferase 6A multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT6A mRNA CTD PMID:27188386 NCBI chr16:73,942,669...74,020,750
Ensembl chr16:73,943,455...74,023,005
JBrowse link
G Kat7 lysine acetyltransferase 7 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT7 mRNA
panobinostat results in decreased expression of KAT7 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:83,095,067...83,128,342
Ensembl chr10:83,095,068...83,128,297
JBrowse link
G Kbtbd11 kelch repeat and BTB domain containing 11 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of KBTBD11 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KBTBD11 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr16:79,696,395...79,716,129
Ensembl chr16:79,696,891...79,700,992
JBrowse link
G Kcna7 potassium voltage-gated channel subfamily A member 7 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of KCNA7 mRNA CTD PMID:21791302 NCBI chr 1:101,397,828...101,403,320
Ensembl chr 1:101,397,828...101,403,320
JBrowse link
G Kcnc1 potassium voltage-gated channel subfamily C member 1 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNC1 mRNA
panobinostat results in decreased expression of KCNC1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:102,414,352...102,456,718
Ensembl chr 1:102,414,625...102,456,411
JBrowse link
G Kcnd2 potassium voltage-gated channel subfamily D member 2 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA
panobinostat results in decreased expression of KCND2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:48,309,283...48,816,804 JBrowse link
G Kcng1 potassium voltage-gated channel modifier subfamily G member 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of KCNG1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNG1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:165,020,230...165,040,966
Ensembl chr 3:165,020,230...165,039,707
JBrowse link
G Kcnh5 potassium voltage-gated channel subfamily H member 5 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNH5 mRNA
panobinostat results in decreased expression of KCNH5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:97,872,831...98,157,087
Ensembl chr 6:97,872,831...98,157,087
JBrowse link
G Kcnj13 potassium inwardly-rectifying channel, subfamily J, member 13 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA
panobinostat results in decreased expression of KCNJ13 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:94,486,719...94,495,333
Ensembl chr 9:94,487,224...94,495,333
JBrowse link
G Kcnj3 potassium inwardly-rectifying channel, subfamily J, member 3 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA CTD PMID:27188386 NCBI chr 3:41,019,898...41,181,070
Ensembl chr 3:41,019,898...41,181,070
JBrowse link
G Kcnk1 potassium two pore domain channel subfamily K member 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNK1 mRNA CTD PMID:27188386 NCBI chr19:58,823,836...58,862,926
Ensembl chr19:58,823,814...58,862,926
JBrowse link
G Kcnk10 potassium two pore domain channel subfamily K member 10 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA
panobinostat results in decreased expression of KCNK10 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:122,417,079...122,549,532
Ensembl chr 6:122,419,046...122,545,899
JBrowse link
G Kcnmb4 potassium calcium-activated channel subfamily M regulatory beta subunit 4 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of KCNMB4 mRNA CTD PMID:21791302 NCBI chr 7:59,461,808...59,514,759
Ensembl chr 7:59,461,799...59,514,939
JBrowse link
G Kcnn3 potassium calcium-activated channel subfamily N member 3 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNN3 mRNA
panobinostat results in decreased expression of KCNN3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:188,837,280...188,991,794
Ensembl chr 2:188,844,073...188,988,774
JBrowse link
G Kcnv1 potassium voltage-gated channel modifier subfamily V member 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNV1 mRNA CTD PMID:27188386 NCBI chr 7:84,016,864...84,023,205
Ensembl chr 7:84,015,207...84,023,316
JBrowse link
G Kctd1 potassium channel tetramerization domain containing 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD1 mRNA
panobinostat results in increased expression of KCTD1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:6,374,778...6,474,990
Ensembl chr18:6,374,778...6,474,990
JBrowse link
G Kctd12 potassium channel tetramerization domain containing 12 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCTD12 mRNA
panobinostat results in increased expression of KCTD12 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:87,384,632...87,390,627 JBrowse link
G Kdr kinase insert domain receptor multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA CTD PMID:27188386 NCBI chr14:34,727,677...34,787,127
Ensembl chr14:34,727,623...34,787,183
JBrowse link
G Kif13a kinesin family member 13A decreases expression ISO panobinostat results in decreased expression of KIF13A mRNA CTD PMID:26272509 NCBI chr17:18,151,582...18,335,027
Ensembl chr17:18,151,982...18,335,019
JBrowse link
G Kif28p kinesin family member 28, pseudogene multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIF28P mRNA CTD PMID:27188386 NCBI chr13:97,969,335...98,023,829
Ensembl chr13:97,969,335...98,023,829
JBrowse link
G Kif5c kinesin family member 5C multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of KIF5C mRNA CTD PMID:21791302 NCBI chr 3:35,014,157...35,257,417
Ensembl chr 3:35,014,538...35,257,407
JBrowse link
G Kifap3 kinesin-associated protein 3 increases expression
multiple interactions
ISO panobinostat results in increased expression of KIFAP3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIFAP3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:82,072,497...82,217,256
Ensembl chr13:82,072,497...82,217,252
JBrowse link
G Kiss1r KISS1 receptor multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KISS1R mRNA CTD PMID:27188386 NCBI chr 7:12,606,210...12,609,868
Ensembl chr 7:12,606,210...12,609,868
JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase increases expression
multiple interactions
ISO panobinostat results in increased expression of KIT mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIT mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:35,072,131...35,149,638
Ensembl chr14:35,072,108...35,149,610
JBrowse link
G Kitlg KIT ligand increases expression
multiple interactions
ISO panobinostat results in increased expression of KITLG mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KITLG mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:42,269,784...42,351,054
Ensembl chr 7:42,269,784...42,351,054
JBrowse link
G Kiz kizuna centrosomal protein decreases expression
multiple interactions
ISO panobinostat results in decreased expression of KIZ mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIZ mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:141,067,981...141,173,738
Ensembl chr 3:141,068,023...141,173,858
JBrowse link
G Klf15 Kruppel-like factor 15 increases expression
multiple interactions
ISO panobinostat results in increased expression of KLF15 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF15 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:122,364,688...122,377,690
Ensembl chr 4:122,365,093...122,377,659
JBrowse link
G Klf4 Kruppel like factor 4 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF4 mRNA CTD PMID:27188386 NCBI chr 5:72,283,311...72,287,669
Ensembl chr 5:72,283,313...72,287,669
JBrowse link
G Klf5 Kruppel-like factor 5 increases expression
multiple interactions
ISO panobinostat results in increased expression of KLF5 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:83,703,796...83,722,921
Ensembl chr15:83,703,791...83,722,921
JBrowse link
G Klf6 Kruppel-like factor 6 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF6 mRNA
panobinostat results in increased expression of KLF6 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:67,887,939...67,945,052
Ensembl chr17:67,887,939...67,945,037
JBrowse link
G Klhl14 kelch-like family member 14 increases expression ISO panobinostat results in increased expression of KLHL14 mRNA CTD PMID:26272509 NCBI chr18:12,526,627...12,640,381
Ensembl chr18:12,528,111...12,640,716
JBrowse link
G Klk10 kallikrein related-peptidase 10 multiple interactions ISO [Cisplatin co-treated with panobinostat] affects the expression of KLK10 mRNA CTD PMID:21791302 NCBI chr 1:99,718,275...99,722,743
Ensembl chr 1:99,718,907...99,722,284
JBrowse link
G Klk8 kallikrein related-peptidase 8 multiple interactions
increases expression
ISO [Cisplatin co-treated with Panobinostat] affects the expression of KLK8 mRNA; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLK8 mRNA
panobinostat results in increased expression of KLK8 mRNA
CTD PMID:21791302, PMID:26272509, PMID:27188386 NCBI chr 1:99,735,168...99,742,011
Ensembl chr 1:99,734,993...99,742,009
JBrowse link
G Klrg2 killer cell lectin like receptor G2 increases expression
multiple interactions
ISO panobinostat results in increased expression of KLRG2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLRG2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:66,370,674...66,381,351
Ensembl chr 4:66,371,511...66,380,734
JBrowse link
G Kremen1 kringle containing transmembrane protein 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of KREMEN1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KREMEN1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:85,441,209...85,503,661
Ensembl chr14:85,438,707...85,484,275
JBrowse link
G Krt18 keratin 18 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA
panobinostat results in increased expression of KRT18 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:143,629,455...143,633,131
Ensembl chr 7:143,629,455...143,633,131
JBrowse link
G Krt19 keratin 19 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT19 mRNA CTD PMID:27188386 NCBI chr10:88,055,843...88,060,560
Ensembl chr10:88,055,841...88,060,561
JBrowse link
G Krt8 keratin 8 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT8 mRNA
panobinostat results in increased expression of KRT8 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:143,596,511...143,603,745
Ensembl chr 7:143,596,511...143,603,803
JBrowse link
G L1cam L1 cell adhesion molecule multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of L1CAM mRNA
panobinostat results in increased expression of L1CAM mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:156,901,244...156,928,064
Ensembl chr  X:156,909,913...156,928,057
JBrowse link
G L1td1 LINE-1 type transposase domain containing 1 increases expression ISO panobinostat results in increased expression of L1TD1 mRNA CTD PMID:26272509 NCBI chr 5:117,347,998...117,361,012
Ensembl chr 5:117,354,794...117,360,654
JBrowse link
G Lacc1 laccase domain containing 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of LACC1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACC1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:59,199,537...59,217,200
Ensembl chr15:59,209,829...59,215,803
JBrowse link
G Lactb lactamase, beta increases expression
multiple interactions
ISO panobinostat results in increased expression of LACTB mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:72,750,174...72,766,307
Ensembl chr 8:72,750,171...72,766,389
JBrowse link
G Lama2 laminin subunit alpha 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of LAMA2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:18,491,264...19,143,486
Ensembl chr 1:18,491,384...19,143,269
JBrowse link
G Lama4 laminin subunit alpha 4 increases expression
multiple interactions
ISO panobinostat results in increased expression of LAMA4 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr20:44,060,715...44,201,966
Ensembl chr20:44,060,731...44,209,614
JBrowse link
G Lamc2 laminin subunit gamma 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of LAMC2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMC2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:70,566,643...70,632,126
Ensembl chr13:70,566,643...70,626,252
JBrowse link
G Lamp2 lysosomal-associated membrane protein 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of LAMP2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMP2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:124,722,628...124,766,079
Ensembl chr  X:124,722,628...124,766,044
JBrowse link
G Layn layilin increases expression
multiple interactions
ISO panobinostat results in increased expression of LAYN mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAYN mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:55,447,203...55,469,420
Ensembl chr 8:55,447,709...55,467,688
JBrowse link
G Lctl lactase-like decreases expression
multiple interactions
ISO panobinostat results in decreased expression of LCTL mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:69,070,340...69,090,405
Ensembl chr 8:69,070,994...69,086,992
JBrowse link
G Ldhd lactate dehydrogenase D increases expression
multiple interactions
ISO panobinostat results in increased expression of LDHD mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LDHD mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr19:43,826,989...43,848,937
Ensembl chr19:43,826,993...43,848,937
JBrowse link
G Lgals1 galectin 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS1 mRNA CTD PMID:27188386 NCBI chr 7:120,153,184...120,156,290
Ensembl chr 7:120,153,184...120,156,289
JBrowse link
G Lgals3 galectin 3 increases expression
multiple interactions
ISO panobinostat results in increased expression of LGALS3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LGALS3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:24,153,602...24,165,537
Ensembl chr15:24,141,651...24,165,537
JBrowse link
G Lhfpl6 LHFPL tetraspan subfamily member 6 increases expression
multiple interactions
ISO panobinostat results in increased expression of LHFPL6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHFPL6 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:142,262,236...142,461,980
Ensembl chr 2:142,262,236...142,461,980
JBrowse link
G Lhx2 LIM homeobox 2 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA
panobinostat results in decreased expression of LHX2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:22,628,674...22,658,447
Ensembl chr 3:22,640,545...22,658,446
JBrowse link
G Lhx8 LIM homeobox 8 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA
panobinostat results in increased expression of LHX8 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:260,572,205...260,598,744
Ensembl chr 2:260,574,190...260,596,777
JBrowse link
G Lifr LIF receptor subunit alpha multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA
panobinostat results in increased expression of LIFR mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:56,424,910...56,489,346
Ensembl chr 2:56,426,367...56,489,415
JBrowse link
G Lim2 lens intrinsic membrane protein 2 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIM2 mRNA CTD PMID:27188386 NCBI chr 1:98,495,082...98,501,248
Ensembl chr 1:98,495,082...98,501,249
JBrowse link
G Limch1 LIM and calponin homology domains 1 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of LIMCH1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIMCH1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:42,760,363...43,072,976
Ensembl chr14:42,762,587...43,072,843
JBrowse link
G Lin28b lin-28 homolog B multiple interactions
decreases expression
affects expression
ISO (+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LIN28B mRNA]; (+)-JQ1 compound promotes the reaction [Panobinostat results in decreased expression of LIN28B protein]; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LIN28B mRNA]; Panobinostat promotes the reaction [(+)-JQ1 compound results in decreased expression of LIN28B protein]
panobinostat results in decreased expression of LIN28B protein
panobinostat affects the expression of LIN28B mRNA
CTD PMID:26733615 NCBI chr20:50,482,536...50,580,273
Ensembl chr20:50,486,809...50,564,987
JBrowse link
G Lingo2 leucine rich repeat and Ig domain containing 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of LINGO2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINGO2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:51,466,367...51,638,161 JBrowse link
G Lix1 limb and CNS expressed 1 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of LIX1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIX1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:59,156,021...59,212,878
Ensembl chr 1:59,156,251...59,214,452
JBrowse link
G Lman1 lectin, mannose-binding, 1 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of LMAN1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMAN1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr18:61,683,377...61,707,344
Ensembl chr18:61,685,117...61,707,317
JBrowse link
G Lmf1 lipase maturation factor 1 increases expression ISO panobinostat results in increased expression of LMF1 mRNA CTD PMID:26272509 NCBI chr10:14,945,185...15,031,855
Ensembl chr10:14,945,265...15,031,942
JBrowse link
G Lmo2 LIM domain only 2 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO2 mRNA
panobinostat results in decreased expression of LMO2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:93,909,156...93,931,888
Ensembl chr 3:93,909,156...93,931,871
JBrowse link
G Lmo3 LIM domain only 3 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of LMO3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:172,942,023...173,005,630
Ensembl chr 4:172,942,020...173,005,634
JBrowse link
G Lmo7 LIM domain 7 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LMO7 mRNA CTD PMID:27188386 NCBI chr15:86,242,911...86,458,512
Ensembl chr15:86,243,148...86,457,739
JBrowse link
G Lnx1 ligand of numb-protein X 1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LNX1 mRNA
panobinostat results in increased expression of LNX1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:36,047,136...36,149,740
Ensembl chr14:36,047,144...36,149,740
JBrowse link
G LOC100302372 hypothetical protein LOC100302372 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA
panobinostat results in increased expression of KIAA0040 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr13:77,784,516...77,822,333
Ensembl chr13:77,784,808...77,822,333
JBrowse link
G LOC100361016 oocyte specific homeobox 5-like increases expression
multiple interactions
ISO Panobinostat results in increased expression of VENTX mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VENTX mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr  X:93,064,417...93,067,181
Ensembl chr  X:93,064,686...93,065,675
JBrowse link
G LOC100912195 protein BEX1-like multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA
panobinostat results in increased expression of BEX5 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:116,565,779...116,567,283
Ensembl chr 1:116,565,790...116,567,189
JBrowse link
G LOC102551394 RING finger protein 175-like multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RNF175 mRNA
panobinostat results in decreased expression of RNF175 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:182,806,670...182,829,114 JBrowse link
G LOC102555635 zinc finger protein 39-like decreases expression
multiple interactions
ISO Panobinostat results in decreased expression of ZNF785 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF785 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:45,193,771...45,211,045
Ensembl chr10:45,193,989...45,211,044
JBrowse link
G LOC103690068 immortalization up-regulated protein-like multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA
panobinostat results in increased expression of C19ORF33 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:87,190,704...87,192,296
Ensembl chr 1:88,192,370...88,193,346
Ensembl chr 1:88,192,370...88,193,346
JBrowse link
G LOC498368 similar to RIKEN cDNA 0610040J01 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C4ORF19 mRNA CTD PMID:27188386 NCBI chr14:46,050,752...46,134,770
Ensembl chr14:46,050,750...46,054,022
JBrowse link
G LOC685680 similar to TPA-induced transmembrane protein increases expression
multiple interactions
ISO panobinostat results in increased expression of C3ORF52 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C3ORF52 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr11:60,138,729...60,165,460
Ensembl chr11:60,140,130...60,164,655
JBrowse link
G LOC688459 hypothetical protein LOC688459 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of C6ORF141 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C6ORF141 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 9:23,420,654...23,424,832
Ensembl chr 9:23,420,654...23,424,832
JBrowse link
G LOC689959 hypothetical protein LOC689959 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF52 mRNA CTD PMID:27188386 NCBI chr 8:55,164,736...55,174,613
Ensembl chr 8:55,164,736...55,171,718
JBrowse link
G LOC691113 hypothetical protein LOC691113 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of C2ORF68 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C2ORF68 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:100,208,612...100,215,824
Ensembl chr 4:100,209,951...100,212,122
JBrowse link
G Lpar6 lysophosphatidic acid receptor 6 increases expression
multiple interactions
ISO panobinostat results in increased expression of LPAR6 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPAR6 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:55,126,953...55,128,762
Ensembl chr15:55,126,953...55,128,761
JBrowse link
G Lrig1 leucine-rich repeats and immunoglobulin-like domains 1 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of LRIG1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRIG1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:126,615,998...126,717,434
Ensembl chr 4:126,617,244...126,644,895
JBrowse link
G Lrp12 LDL receptor related protein 12 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of LRP12 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP12 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 7:78,859,784...78,930,850
Ensembl chr 7:78,859,784...78,930,832
JBrowse link
G Lrp2 LDL receptor related protein 2 multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP2 mRNA
panobinostat results in decreased expression of LRP2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:55,665,153...55,822,484
Ensembl chr 3:55,665,145...55,822,551
JBrowse link
G Lrp8 LDL receptor related protein 8 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRP8 mRNA CTD PMID:27188386 NCBI chr 5:127,404,348...127,476,636
Ensembl chr 5:127,404,450...127,476,641
JBrowse link
G Lrrc17 leucine rich repeat containing 17 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC17 mRNA
panobinostat results in increased expression of LRRC17 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:10,108,184...10,138,652
Ensembl chr 4:10,108,192...10,138,652
JBrowse link
G Lrrc3b leucine rich repeat containing 3B multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC3B mRNA
panobinostat results in decreased expression of LRRC3B mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr15:11,221,161...11,299,563
Ensembl chr15:11,298,478...11,299,257
JBrowse link
G Lrrc55 leucine rich repeat containing 55 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of LRRC55 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:72,589,840...72,605,089
Ensembl chr 3:72,589,842...72,602,548
JBrowse link
G Lrrc8b leucine rich repeat containing 8 VRAC subunit B multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC8B mRNA
panobinostat results in decreased expression of LRRC8B mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr14:5,414,872...5,482,004
Ensembl chr14:5,418,741...5,428,757
JBrowse link
G Lrrc8e leucine rich repeat containing 8 VRAC subunit E multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRC8E mRNA
panobinostat results in increased expression of LRRC8E mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr12:2,557,267...2,568,416
Ensembl chr12:2,557,275...2,568,382
JBrowse link
G Lrrfip1 LRR binding FLII interacting protein 1 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRFIP1 mRNA CTD PMID:27188386 NCBI chr 9:98,139,484...98,268,148
Ensembl chr 9:98,190,829...98,257,735
JBrowse link
G Lrrn3 leucine rich repeat neuronal 3 multiple interactions
increases expression
affects expression
ISO (+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LRRN3 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LRRN3 mRNA]
panobinostat results in increased expression of LRRN3 mRNA
panobinostat affects the expression of LRRN3 mRNA
CTD PMID:26272509, PMID:26733615, PMID:27188386 NCBI chr 6:61,374,328...61,405,195
Ensembl chr 6:61,374,328...61,405,195
JBrowse link
G Lrrn4 leucine rich repeat neuronal 4 multiple interactions ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN4 mRNA CTD PMID:27188386 NCBI chr 3:125,521,879...125,547,685
Ensembl chr 3:125,523,781...125,533,600
JBrowse link
G LRRTM1 leucine rich repeat transmembrane neuronal 1 multiple interactions
affects expression
ISO (+)-JQ1 compound promotes the reaction [Panobinostat affects the expression of LRRTM1 mRNA]; [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRTM1 mRNA; Panobinostat promotes the reaction [(+)-JQ1 compound affects the expression of LRRTM1 mRNA]
panobinostat affects the expression of LRRTM1 mRNA
CTD PMID:26733615, PMID:27188386 NCBI chr 4:108,300,927...108,316,373
Ensembl chr 4:108,301,129...108,316,373
JBrowse link
G Ly75 lymphocyte antigen 75 increases expression
multiple interactions
ISO panobinostat results in increased expression of LY75 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LY75 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:46,369,749...46,457,182
Ensembl chr 3:46,365,165...46,457,201
JBrowse link
G Lyn LYN proto-oncogene, Src family tyrosine kinase increases expression
multiple interactions
ISO panobinostat results in increased expression of LYN mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYN mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 5:16,526,058...16,642,648
Ensembl chr 5:16,526,058...16,642,648
JBrowse link
G Lypd3 Ly6/Plaur domain containing 3 increases expression
multiple interactions
ISO panobinostat results in increased expression of LYPD3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD3 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 1:81,499,856...81,504,306
Ensembl chr 1:81,499,821...81,504,318
JBrowse link
G Lysmd2 LysM domain containing 2 increases expression
multiple interactions
ISO panobinostat results in increased expression of LYSMD2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYSMD2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 8:82,560,363...82,576,662
Ensembl chr 8:82,560,761...82,577,019
JBrowse link
G Lyzl6 lysozyme-like 6 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYZL6 mRNA
panobinostat results in increased expression of LYZL6 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr10:91,694,547...91,701,428
Ensembl chr10:91,694,547...91,699,424
JBrowse link
G Lzts1 leucine zipper tumor suppressor 1 increases expression
multiple interactions
ISO panobinostat results in increased expression of LZTS1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LZTS1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr16:22,250,452...22,306,667
Ensembl chr16:22,250,470...22,306,662
JBrowse link
G Mab21l2 mab-21 like 2 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of MAB21L2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAB21L2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 2:185,849,749...185,852,833
Ensembl chr 2:185,850,232...185,852,759
JBrowse link
G Macc1 MET transcriptional regulator MACC1 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA
panobinostat results in increased expression of MACC1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 6:147,315,232...147,392,530
Ensembl chr 6:147,315,328...147,394,269
JBrowse link
G Macrod2 mono-ADP ribosylhydrolase 2 decreases expression
multiple interactions
ISO panobinostat results in decreased expression of MACROD2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROD2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 3:135,729,839...136,422,082 JBrowse link
G Macroh2a1 macroH2A.1 histone multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA
Panobinostat results in decreased expression of MACROH2A1 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:9,282,109...9,344,698
Ensembl chr17:9,282,675...9,344,678
JBrowse link
G Mafb MAF bZIP transcription factor B increases expression ISO panobinostat results in increased expression of MAFB mRNA CTD PMID:26272509 NCBI chr 3:156,338,993...156,340,913
Ensembl chr 3:156,339,004...156,340,913
JBrowse link
G Magi2 membrane associated guanylate kinase, WW and PDZ domain containing 2 multiple interactions
increases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAGI2 mRNA
panobinostat results in increased expression of MAGI2 mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr 4:10,995,241...12,472,423
Ensembl chr 4:10,995,234...11,610,518
JBrowse link
G Mak male germ cell-associated kinase multiple interactions
decreases expression
ISO [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAK mRNA
panobinostat results in decreased expression of MAK mRNA
CTD PMID:26272509, PMID:27188386 NCBI chr17:21,531,651...21,567,742
Ensembl chr17:21,521,505...21,568,440
JBrowse link
G Man1a1 mannosidase, alpha, class 1A, member 1 increases expression
multiple interactions